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ABSTRACT 
 
The immune system is important for the prevention of cancer and formed the basis 
of cancer immunotherapy.  That is, enhancement of the immune response for the treatment 
of malignant cancer cells.  The field has undergone significant progress to include the use 
of checkpoint inhibitors, monoclonal antibodies and cytokine therapies.  In addition, a 
cancer vaccine, composed of tumor associated antigens (TAAs) and vaccine adjuvant, is 
particularly promising.  Effective vaccines can mobilize tumor-specific CD8 T cells to kill 
selectively tumor cells with cytotoxic granules and secrete IFN-ɣ that sensitize tumors to 
be susceptible to effector immune cells. Additionally, activated CD8 T cells become 
memory cells and can respond to same TAA-epitopes, which can be effective for long-term 
protective immunity to inhibit cancer recurrence.  
Activation of dendritic cells (DCs), which are the main antigen-presenting cells 
(APCs), is critical for T cell immunity. To an elicit tumor-specific CD8 T cell response, 
DCs have to process and present TAAs to CD8 T cells through the major histocompatibility 
complex (MHC) I. Moreover, co-stimulatory signals and pro-inflammatory cytokines are 
required to stimulate CD 8 T cells. However, CD8 T cell anergy and exhaustion will occur 
if TAA treatment is not sufficiently immunogenic to trigger DC activation. Therefore, 
development of immunostimulatory adjuvant that can trigger DC activation can enhance 
therapeutic efficacy of cancer vaccines.  
Imidazoquinoline-structured synthetic toll-like receptor (TLR) 7/8 agonists are 
strong cytokine inducers that can be a potent vaccine adjuvant. TLR7/8 ligation can 
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activate MyD88 signaling pathways and stimulate DCs to upregulate co-stimulatory 
molecules and secrete pro-inflammatory cytokines and type I interferons. However, 
TLR7/8 agonists lack prominent efficacy in vivo due to the rapid clearance from the 
injection site. Following subcutaneous (SC) injection, small molecules enter the systemic 
circulation via blood capillaries and only small portion can reach the draining lymph nodes. 
Therefore, our goal was to develop a SC injectable drug carrier that can more efficiently 
deliver as well as prolong duration of at the site of action of TLR7/8 agonists. 
In this study, we fabricated poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) 
containing TLR7/8 agonists. Nanoparticulate delivery of TLR7/8 agonist showed enhanced 
DC activation and antigen-presentation compared to the soluble form of TLR7/8 agonists. 
When combined with peptide/tumor cell lysate-based antigens, NPs potentiated the 
antigen-specific CD8 T cell expansion and increased cytotoxic functions, which resulted 
in enhanced efficacy in both prophylactic and therapeutic tumor models.  
To further enhance endo/lysosomal delivery of TLR7/8 agonists in PLGA NPs, we 
included a sodium bicarbonate-mediated gas-generating system that is acidic pH-
responsive. This approach resulted in 33-fold greater amount of TLR7/8 agonists 
encapsulated within the NPs.  More importantly, the PLGA NP immunization elicited a 
stronger CD8 T cell response compared to conventional PLGA NPs, which in turn, 
enhanced therapeutic efficacy.  
As tumor microenvironment is immune suppressive, we examined whether 
modulation of tumor microenvironment can enhance the therapeutic efficacy of cancer 
vaccine. We reduced the immune suppressive cells including myeloid-derived suppressive 
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cells (MDSCs) and regulatory T cells (Tregs) by daily oral dosing of a tyrosine kinase 
inhibitor (TKI), sunitinib. Additionally, we adapted an anti-PD-L1 antibody to block 
programmed death ligand 1 (PD-L1) expressed on tumor-associated (M2) macrophages 
and MDSCs that exhaust CD8 T cells, to augment the CD8 T cell activation at the tumor. 
In our study, combination of sunitinib and PD-L1 blockade significantly decreased the 
immune suppressive cell population and reduced PD-L1 expression on these cells. We also 
examined if nanoparticulate delivery of TLR7/8 agonist can potentiate NK cell-mediated 
cancer immunotherapy through its known effect on TH1 immunity.  Antibody-dependent 
cellular cytotoxicity (ADCC) of monoclonal antibodies was found to be augmented in 
response to TLR7/8 agonist encapsulating NPs as a vaccine adjuvant. 
Overall, our studies demonstrate that PLGA NPs broaden the application of TLR7/8 
agonists for improved cancer treatment.  Moreover, this platform holds promise to enhance 
the efficacy of cancer vaccines composed of tumor associated antigens (TAAs) and vaccine 
adjuvant 
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1.1. Introduction to cancer immunotherapy 
Cancer immunotherapy involving the use of host immune cells to attack the tumor 
cells has shown promising results in both pre-clinical and clinical studies1. Cancer 
immunotherapeutic strategies, including monoclonal antibodies, adoptive cell transfer, 
checkpoint inhibitors, and cancer vaccines, rely on mobilizing cytotoxic CD8 T cells and 
natural killer (NK) cells2. However, anti-tumor efficacy of immunotherapeutics is often 
hampered by insufficient potency to stimulate desired effector cells and the immune-
suppressive tumor microenvironment3.  Thus, improvement of the therapeutic outcome 
requires both potentiating the anti-tumor immune response as well as modulating the tumor 
microenvironment. To achieve these goals, potent immune stimulant and combination 
therapy with reagent(s) to downregulate immune-suppressive mechanisms were 
investigated.  In this chapter, the background information that led to our specific 
approaches is provided.  The remaining chapters describe the experimental details, results 
and discussion.  The concluding chapter provides a summary and the significance of this 
work and possible directions for future research. 
 
1.2. Cancer immunotherapeutics 
 Monoclonal antibodies play multiple roles in cancer immunotherapy with their 
ability to block tumor-promoting receptors, activating or inhibiting other immune cells and 
inducing antibody-dependent cellular cytotoxicity (ADCC) responses4. Monoclonal 
antibodies that target the tumor-specific receptors include cetuximab, which targets 
epidermal growth factor receptor (EGFR) and trastzumab, which targets human epidermal 
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growth factor receptor 2 (HER2)5,6. These antibodies block the tumor progression signaling 
and elicit ADCC responses to kill tumor cells. Tumor-angiogenic growth factors, including 
vascular endothelial growth factors (VEGF) and platelet-derived growth factor (PDGF), 
can be inhibited by bevacizumab7. Monoclonal antibodies that target leukemia/lymphoma 
related molecules including CD20, CD30, CD33 and CD52 are also approved therapeutics 
8. 
 Checkpoint inhibitors are therapeutics that promote an anti-tumor response by 
neutralizing the inhibitory signals, which deactivate T cells and NK cells9. Cytotoxic T 
lymphocyte antigen 4 (CTLA4) is a homologue of CD8 T cell activating molecule CD2810. 
CTLA4 is expressed on CD8 T cells and can be activated by co-stimulatory molecules 
CD80 and CD86 of dendritic cells (DCs) and macrophages. Therefore, anti-CTLA4 
antibodies can block the inhibitory CTLA4 and enhance CD8 T cell stimulatory CD28-
CD80/86 signaling, which leads to activation of effector CD8 T cells.  
Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) signaling is also 
a major tumor escape mechanism. PD-L1 is expressed on tumor cells, monocytes, 
macrophages and myeloid-derived suppressive cells (MDSCs). PD-L1 ligates PD-1 
expressed on CD8 T cells and NK cells and cause exhaustion of these cells 11. It has been 
reported that upregulation of PD-L1 on solid tumors reduces the tumor-infiltration of T 
cells. With these aspects, PD-L1 is reported to be associated with poor prognosis of solid 
tumors and thereby is used as a biomarker for cancer immunotherapy12,13.  
 Adoptive cell transfer (ACT) therapies that infuse effector cells to donor cells are 
also clinically used. ACT strategies include infusion of ex vivo stimulated T cells that were 
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isolated from patient tumors14. Engineered T cells that possess chimeric antigen receptor 
(CAR) or T cell receptor (TCR) are also a potent source for ACT-based cancer 
immunotherapy 15.  
 
1.3. Cancer vaccine strategies and challenges 
 Cancer vaccines are developed to mobilize cytotoxic CD8 T cells and NK cells. To 
elicit a tumor-specific immune response, sufficient tumor-associated antigens (TAAs) must 
be provided to antigen presenting cells (APCs) including DCs, macrophages and B cells 16. 
Immunostimulatory adjuvants are often required to enhance the activity of APCs to 
produce a sufficient immune response.  
 The first cancer vaccine was comprised of autologous tumor cells collected from 
patients. The benefit of autologous tumor cells is the large repertoire of antigens that covers 
TAAs of the patient’s tumor 17. Allogeneic tumor cell vaccines, which are mixtures of 
established immunogenic tumor cell lines, are also used for the treatment of melanoma and 
non-small cell lung cancer 18. However, due to the limited availability of patients’ samples 
and intricate procedures to prepare tumor cell vaccines, TAA associated peptide/proteins 
were investigated.  As opposed to tumor cell vaccines, TAA peptide/proteins are cost-
effective and can elicit TAA-specific T cell response and as such represent an advanced 
antigen source for cancer immunotherapy 19.  
There are several types of TAAs. Antigens that are normally muted in the normal 
tissue but can be reactivated in tumor cells include MAGE-1, NY-ESO-1, BAGE, and 
SSX-2, which are cancer-testis antigens 20. Antigens that are highly expressed compared 
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to normal tissues include melanoma antigens (gp100, MART-1) 21, prostate cancer antigens 
(PSA, PSP) 22, MUC-1 and HER-2 23. Mutated oncogenes, including RAS and BRAF, are 
reported to be uniquely expressed on the tumor cells 24 and therefore may be potent TAA 
peptide vaccines.  
To elicit a TAA-specific T cell response, DCs need to be provided with sufficient 
amount of TAAs and be in mature state to present TAA to T cells and upregulate 
stimulatory signals. However, tumor cells and peptide/protein TAAs are often not 
sufficiently immunogenic to trigger a T cell response.  This then requires a 
immunostimulant for promoting DC activation to elicit a strong T cell response25. For this 
purpose, irradiated tumor cells and co-incubation with stimulatory cytokines including IL-
12 26 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 27 were 
investigated to enhance the immunogenicity of tumor cells.  Toll-like receptor (TLR) 
agonists 28 are also actively being examined in clinical trials as a vaccine adjuvant for 
peptide/protein vaccines. 
 
1.4. TLR signaling promotes activation of APCs 
 Host immune system detect the pathogens via several mechanisms. TLRs are part 
of pattern recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPs) which include flagellin, bacteria, virus, nucleic acids and toxins29. TLRs 
are mainly expressed on the APCs including DCs, macrophages, and B cells and also on 
mast cells, monocytes and epithelium cells. Expression of TLRs varies among species, and 
TLR 1~10 are reported in human29. In humans, TLRs 1, 2, 4, 6 and 10 are located at the 
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cellular membrane, while TLRs 3, 7, 8, and 9 are located in the intracellular 
endo/lysosomes. Ligands for TLRs can be divided to three categories; TLRs 1, 2, 4, 6 
recognize lipids, TLR5 recognizes proteins and intracellular TLRs 3, 7, 8, and 9 recognize 
nucleic acids.  
 Upon ligation, TLRs 1, 2, 5, 6, 7, 8, and 9 activate myeloid differentiation primary-
response gene 88 (MyD88) and TLR3 and 4 as well as toll/IL-1R (TIR) domain-containing 
adaptor protein inducing IFNβ (TRIF) signaling pathways30. MyD88 signaling activates 
interferon-regulatory factor (IRF)7, nuclear factor-kappa B (NF‑κB) and mitogen-activated 
protein kinases (MAPKs) that results in production of multiple IFN type I, including IFNα, 
IFNβ, IFNλ and IFNω. Furthermore, MyD88 signaling upregulates co-stimulatory 
molecules CD40, CD80 and CD86 and triggers secretion of pro-inflammatory cytokines, 
such as IL-1β, IL-12, IL-18, tumor necrosis factor alpha (TNF-α), and interferon gamma 
(IFN-ɣ). In addition to NF‑κB and MAPKs, TRIF signaling activates IRF 3 to trigger IFN 
and co-stimulatory responses.  
With these aspects, TLR agonists were examined as immunostimulatory adjuvants 
of cancer vaccines to enhance the immunogenicity of TAAs. TLR2 agonist (polysaccharide 
krestin; PSK), TLR 3 agonist (polyriboinosinic-polyribocytidylic acid-polylysine 
carboxymethylcellulose; poly ICLC), TLR 4 agonist (lipopolysaccharide; LPS) and TLR9 
agonist (CpG Oligodeoxynucleotide; CpG ODN) combined with TAAs including NY-
SEO-1, MUC-1 and MART1 showed promising anticancer efficacy in pre-clinical studies 
and clinical trials 31–34. 
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1.5. TLR7/8 agonists for cancer immunotherapy 
Synthetic imidazoquinoline derivatives are potent TLR7 or 8 specific or 7/8 bi-
specific agonists35. TLR7 selective agonist, named imiquimod, was first introduced in 
1997. Imiquimod was approved by US Food and Drug Administration (FDA) for treatment 
of basal and squamous cell carcinoma and genital warts as a single agent36. Imiquimod 
activates plasmacytoid DCs (pDCs) and macrophages via TLR7 ligation to promote the 
pro-inflmmatory cytokine induction including type I IFN, TNF-ɑ and IL-1237. These 
cytokines induce activation of CD4 T cells, CD8 T cells and NK cells that can kill 
malignant tumor cells38,39. Previous studies also report that imiquimod can induce 
apoptosis of TLR expressing tumors40. These findings suggest that imidazoquinoline-based 
small molecules can foster a potent adaptive immune response, which is important for 
cancer treatment.  
Professor David M. Ferguson (Department of Medicinal Chemistry, University of 
Minnesota) and coworkers have reported a series of imidazoquinoline derivatives that are 
TLR7 or 8-specific or 7/8 mixed agonists41–43. Based on the cytokine induction, TLR7/8 
activities are associated with the C2-alyl chain length of imidazoquinoline structure, where 
butyl and pentyl derivatives potentiate TLR 7 and 8, respectively.  
TLR7 and 8 are both intracellular receptors and recognize single-stranded RNA 
(ssRNA) and ligate NF‑κB signaling pathways. However, recent studies report that, 
although TLR7 and TLR8 recognize similar molecular patterns, they are functionally 
different44. While TLR7 is mainly expressed on pDCs, an induced type I IFN secretion, 
TLR8 is expressed mainly on myeloid DCs (mDCs) and potentiates TNF-ɑ and IFN-ɣ 
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response.  This suggests that TLR7/8 mixed agonists can help foster stronger TH1 
immunity than TLR7 or 8 specific agonists. Previous studies reported that stimulating both 
plasmacytoid and CD8α DCs is required to elicit strong CD8 T cell response45, which 
implies that using TLR7/8 agonist would be more advantageous as immunostimulatory 
adjuvant for cancer immunotherapy.  The chemical structure of the available TLR7/8 
agonist, termed 522, is shown at Figure 1.1. 
 
Figure 1.1. Structures of prototypical TLR7 selective compound imiquimod and dual 
TLR7/8 agonist 522. 
 
1.6. Nanoparticulate drug delivery  
 Nanoparticles (NPs) are an efficient platform for delivery of conventional drugs in 
overcoming the limitations of their inherent pharmacokinetics, both bioavailability and 
elimination.  In addition to small molecular weight drugs, polymeric NPs and liposomes 
have been used to proteins, vectors and nucleic acids46. Discovery of the enhanced 
permeability and retention (EPR) effect47, which explains enhanced accumulation of 
macromolecules via extravasation through leaky blood vessels in the tumor, has led to the 
application of nanoparticles as a carrier for chemotherapy against solid tumors. Two 
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notable examples of FDA-approved nanomedicines are liposomal doxorubicin (Doxil) and 
albumin-bound paclitaxel (Abraxane) 48,49.  
With the successful use of NPs, recent studies have focused on the use of NPs to 
enhance therapeutic efficacy of cancer immunotherapy involving antigens and/or vaccine 
adjuvants50,51. For successful cancer immunotherapy, efficient delivery of 
immunostimulatory molecules to targeted immune cells is critical. In this study, we sought 
to potentiate CD8 T cells by stimulating DCs, which suggest the importance of TLR7/8 
agonist delivery to DCs. Therefore, we compared efficacy of nanoparticulate delivery of 
TLR7/8 agonist relative to a soluble form as immunostimulatory adjuvant for cancer 
immunotherapy. 
  
1.7. PLGA NPs as drug delivery platform of TLR7/8 agonists 
 Poly(lactide-co-glycolide) (PLGA) is a FDA-approved polymer, and the 
biocompatibility and potential cytotoxicity is well-established52. In vivo PLGA undergoes 
decomposition into lactide and glycolide by hydrolysis; hence, it is by definition 
biodegradable53.  Size and drug release kinetics of PLGA NPs can be fine-tuned by 
modulating the composition of PLGA including the molar ratio of lactide to glycolide, 
molecular weight, and terminal groups54.  Additionally, targeting moieties can be readily 
attached to the surface of PLGA NPs by covalent modification of the terminal groupsor by 
adsorption due to its hydrophobicity.  
In addition to these chemical and physical properties, several features further 
suggest PLGA NP as suitable vaccine delivery platform.  DC uptake of antigens and/or 
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immunostimulatory adjuvant is critical to elicit T cell immunity. Previous studies report 
that size, surface charge, hydrophobicity, and shape significantly influence the DC uptake 
of macromolecules55. Among the factors, size plays a critical role as nanoparticles have 
shown superior DC internalization compared to microparticles56. It has also been reported 
that sub-micron sized macromolecules with a size range of 20-200 nm can be efficiently 
internalized into DCs via clathrin-dependent and caveolae-dependent endocytosis 
pathways57. However, endocytosis of micro-sized macromolecules is mainly facilitated 
through pinocytosis and phagocytosis, which is favorable for uptake by macrophages and 
Langerhans cells.  
Previous studies report that PLGA NPs can internalize to in vitro generated DCs 
including human peripheral blood-monocytes-derived DCs, human cord-blood CD34+ 
DCs, and murine bone marrow-derived DCs (BMDCs) within 24 hr of incubation58. 
Efficient DC uptake of PLGA NPs is particularly advantageous for delivery of endosomal 
TLR agonists. TLR3, 7, 8 and 9 are located at the luminal side of endo/lysosome, and thus 
TLR agonists must cross the cellular membrane and internalize into endo/lysosome to 
ligate the TLR signaling. Following endocytosis, PLGA NPs enter endo/lysosomes, which 
is the target site for TLR3, 7, 8 and 9 ligation 59. Therefore, these features suggest that 
PLGA NPs can provide efficient delivery of TLR agonists for DC uptake. 
 
Several studies report that in vivo efficacy of cancer vaccines is often hampered by 
rapid clearance from the injection site60,61.  This leads to insufficient vaccine delivery to 
lymphoid organs and results in sub-optimal therapeutic efficacy. Biodegradation 
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mechanisms facilitate the rapid clearance following injection. Subcutaneous (SC) injection 
is the conventional vaccine administration route, as vaccine components need to migrate 
to draining lymph nodes to stimulate APCs and cytotoxic cells61. SC administration 
delivers the vaccine components to interstitial space of hypodermis composed of 
adipocytes, fibroblast, collagen and glycosaminoglycans (GAGs) 62. PLGA NPs can 
protect encapsulated payloads from biodegradation at the injection site, which is 
particularly important for peptide/protein-based vaccines. PLGA NPs are sufficiently 
robust to protect encapsulated payload, because their glass transition temperature is higher 
than physiological temperature of 37°C and therefore reside in the glassy state. 
Peptide/proteins encapsulated in the polymeric NPs also maintain their activities longer 
than soluble form46,63, when incubated in the mouse/human serum, further supporting the 
rationale of their use.  
Upon SC injection, vaccine components can enter blood circulation or lymphatic 
systems. While blood capillaries are tightly structured, lymphatic vessels are relatively 
more permeable as they lack inter-endothelial tight junctions57. Due to this permeability 
difference, large molecules have limited entry to blood circulation and preferably enter the 
lymphatic system. It was shown that molecules with a molecular weight (MW) of 16 kDa 
or less and/or a size of 10 nm or smaller preferentially enter systemic circulation via blood 
capillaries following the SC injection60,62.  
Blood capillary absorption mediated clearance is problematic for vaccine delivery 
as vaccine components need to migrate to draining lymph nodes to stimulate APCs and 
cytotoxic T cells. Previous studies report that SC injected macromolecules can directly 
  12 
migrate to the lymph node via paracellular uptake or DC-meditated mechanism64,65. It is 
reported that macromolecules with size of 100 ~ 200 nm can directly enter lymphatic 
system via lymphatic capillaries within hours after injection64. On the other hand, 
macromolecules with size of 200 ~ 500 nm can be transported within DCs to the lymphatic 
system. These findings suggest that rapid clearance following SC injection can be reduced 
by nanoparticulate delivery of vaccine components.  
 
Simultaneous co-stimulatory molecule signaling and antigen-presentation by DCs 
is required to elicit antigen-specific CD8 T cell response.  The rationale is that without co-
stimulatory signaling T cell activation fails, and without antigen-presentation non-specific 
T cell expansion occurs66. Therefore, co-delivery of antigen and vaccine adjuvant is critical 
to elicit antigen-specific T cell response 67.  However, co-delivery of TAA and synthetic 
TLR7/8 agonist is challenged by formulation limitations. While most of TLR agonists 
including ICLC, LPS, and CpG ODN are soluble in normal saline and aqueous buffers, 
synthetic TLR7/8 agonists are soluble in organic buffers and have limited solubility in 
normal saline and aqueous buffers.  As such, formulations have been limited to creams and 
gels68,69, and current application of synthetic TLR7/8 agonists are limited to topical 
treatments (ClinicalTrials.gov;  NCT01676831, NCT01808950,) and intratumoral 
injection (NCT02556463).  In clinical studies where topical treatment of TLR7/8 agonists 
were utilized as vaccine adjuvants (NCT01748747, NCT00960752), peptide/protein-based 
TAAs were administered separately by SC injection. Thus, there is a need for an approach 
that can deliver TLR7/8 agonists by SC or IM injection together with TAA-peptides.   
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Encapsulation of TLR7/8 agonists in PLGA NPs can fulfill this need. Previous 
studies reported that PLGA NPs can encapsulate both hydrophilic and hydrophobic 
compounds53. Imidazoquinoline-based synthetic TLR7/8 agonists, which are slightly 
hydrophobic small molecules, can be loaded to PLGA NPs using emulsification solvent 
evaporation methods54. As PLGA NPs can be dispersed in the aqueous buffers, 
encapsulated TLR7/8 agonists can be delivered via conventional vaccine administration 
routes including SC and IM injection, which allows co-delivery of peptide/protein-based 
TAA and TLR7/8 agonists. These aspects suggest PLGA NPs will be not only suitable for 
delivery of TLR7/8 agonist for in vivo immunization but also superior to current 
commercialized formulations.  
 
1.8. Specific aims 
Specific aim 1. Development of drug carrier for TLR7/8 agonist using PLGA NPs 
 We fabricated PLGA NPs as drug carrier for 522 (522NP). The size of PLGA NPs 
was fine-tuned to ~ 200 nm, to facilitate efficient DC uptake and in vivo lymph node 
drainage. Cancer vaccine composed of peptide/tumor cell lysate-based antigen and 522NP 
elicited robust antigen-specific CD8 T cell response, which resulted in enhanced 
prophylactic and therapeutic efficacy in murine tumor models. Result of studies on Specific 
aim 1 is reported at Chapter 2.  
 
Specific aim 2. Adapting pH-responsive drug delivery system to enhance TLR7/8 
agonist-based vaccine  
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We fabricated acidic-pH responsive, gas-generating PLGA NPs by incorporating 
sodium bicarbonate in the NPs (522GGNP). New formulation generated carbon dioxide 
gas in acidic pH, which resulted in rapid release of encapsulated drug. Additionally, new 
formulation showed significantly increased encapsulation efficiency compared to 
conventional PLGA NPs. CD8 T cells and NK cells significantly expanded in mice 
immunized with acidic-pH responsive NPs and showed enhanced therapeutic efficacy 
compared to conventional PLGA NPs. Result of studies on Specific aim 2 is reported at 
Chapter 3.  
 
Specific aim 3. Modulation of tumor microenvironment to enhance therapeutic 
efficacy of nanoparticle-based vaccine 
To enhance the therapeutic efficacy of nanoparticle-based vaccine, we modulated 
immune-suppressive tumor microenvironment. Co-treatment of sunitinib with nanovaccine 
resulted in reduction of MDSCs and Tregs. We further combined anti-PD-L1 antibody to 
inhibit PD-L1/PD-1 signaling. Triple combination therapy with 
nanovaccine+sunitinib+PD-L1 blockade significantly increased the CD8 T cell activation 
at the tumor, and induced antigen-specific memory response. Result of studies on Specific 
aim 3 is reported at Chapter 4.  
 
Specific aim 4. Application of TLR7/8 agonist-encapsulating NPs for antibody-based 
cancer immunotherapy 
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We examined the application of 522GGNP as vaccine adjuvant to augment 
therapeutic efficacy of antibody-based cancer immunotherapy. In our study, 522 triggered 
secretion of IL-12, IL-1β, TNF-α and IFN-ɣ from human peripheral blood mononuclear 
cells (PMBCs), and upregulated co-stimulatory molecules CD70, 80 and 86 on murine 
DCs, all of which are potent modulators of NK cell activation. 522GGNP treatment 
potentiated strong in vivo NK cell cytotoxicity and elongated NK cell activation. When 
combined with cetuximab, 522GGNP treatment significantly enhanced the NK cell 
degranulation and augmented ADCC. Result of studies on Specific aim 4 is reported at 
Chapter 5.  
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Chapter 2. 
 
 
Polymeric nanoparticles encapsulating novel 
TLR7/8 agonists as immunostimulatory 
adjuvants for enhanced cancer immunotherapy 
 
 
 
 
 
 
 
 
*This chapter was published elsewhere70. Reproduced with permission.  
  17 
2.1. Summary 
Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy because of 
their ability to directly kill tumor cells and secrete tumor suppressive cytokines. 
Anticancer vaccines aim to provoke tumor-specific CTL responses, which require 
activation of antigen presenting cells (APCs) including dendritic cells (DCs) and 
macrophages. Therefore, a potent immunostimulatory adjuvant capable of activating 
APCs is an essential component of anticancer vaccines. In this study, we introduce novel 
TLR 7/8 bi-specific agonists that significantly enhance cytokine secretion compared to 
TLR7 mono-selective compounds. Encapsulation of these TLR 7/8 agonists in 
poly(lactide-co-glycolide) (PLGA) nanoparticles increased the co-stimulatory molecule 
expression and antigen presentation via MHC I by DCs compared to the soluble agonist. 
When administered subcutaneously, these nanoparticles migrated to draining lymph node 
and triggered DC activation and expansion. This lead to expansion of antigen-specific 
CD8 T cells and enhanced CTL response, which resulted in significant prophylactic and 
therapeutic efficacy in melanoma, bladder and renal cell carcinoma tumor models. 
Importantly, our studies demonstrate significant reductions in systemic metastasis with 
the nanoparticle vaccine. Our results suggest novel TLR 7/8 agonist-encapsulated 
nanoparticles are potent immunostimulatory adjuvants for cancer immunotherapy. 
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2.2. Introduction 
Anticancer vaccines aim to stimulate the host immune system by providing tumor-
associated antigens (TAAs) in the presence of an immune adjuvant to activate dendritic 
cells (DCs) and trigger tumor-specific immunity 71, and Toll-like receptor (TLR) agonists 
have proven valuable as vaccine adjuvants 72. Activation of TLRs induces NF-κB-mediated 
expression of proinflammatory cytokines and chemokines necessary to generate a robust 
immune response. Of the known human TLRs, the endosomally located TLR7 and TLR8 
are particularly interesting because they can be activated by either single-stranded nucleic 
acids or synthetic small molecules 73,74. We have recently reported a series of highly 
substituted imidazoquinoline-based esters that potently stimulate both TLR7 and 8, 
resulting in higher levels of cytokine production compared to the TLR7-specific agonist 
imiquimod, the only TLR agonist approved for clinical use 42,75. Despite their high in vitro 
TLR agonist activity, small molecules often fail to demonstrate satisfactory in vivo immune 
response 76. Soluble drugs are rapidly cleared from the site of injection, limiting the amount 
of agonist available for activating DCs, a critical early step in the induction of anti-tumor 
immunity. In fact, co-localization of the adjuvant and tumor antigen within DCs could be 
a decisive determinant for the success of adjuvant based cancer immunotherapy 77. 
     Nanoparticles formulated from the biodegradable polymer, poly(D,L-lactide-co-
glycolide) (PLGA), enable greater and sustained cellular delivery of the encapsulated 
payload 78,79. Further, DCs preferentially internalize particles <500 nm in diameter, and 
nanoparticles in this size range stimulate greater CD8 T cell response than micron-size 
particles 58,80. Slow release of TLR agonist from polymeric matrix can facilitate sustained 
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TLR signaling in DCs, which can reduce the need for high and/or repeated dosing. Based 
on these observations, we hypothesized the encapsulation of our new imidazoquinoline-
based TLR7/8 agonists in PLGA nanoparticles would enable significantly improved 
delivery of the agonists to DCs and further enhance their immunomodulatory activity. This 
hypothesis is supported by previous studies showing significant enhancements in immune 
response with the TLR3 agonist polyinosinic:polycytidylic acid and TLR9 agonist 
unmethylated CpG oligodeoxylnucleotide when delivered in polymeric nanoparticles 67,81. 
    In the present study, we selected two of our most promising TLR7/8 bi-specific 
imidazoquinoline-based esters (racemic mixture ‘522’ and its S-configured steroisomer 
‘528’) for encapsulation in PLGA nanoparticles. These two molecules induce high levels 
of pro-inflammatory cytokines, pointing to their strong potential as immunostimulatory 
adjuvants for cancer immunotherapy. The effectiveness of these nanoparticle formulations 
was investigated in multiple tumor models (melanoma, bladder and renal cell carcinoma), 
different vaccine designs (peptide-based, whole tumor cell lysate-based and in situ 
vaccines), and vaccine modalities (prophylactic and therapeutic). These studies show our 
novel TLR7/8 agonists encapsulated in PLGA nanoparticles trigger a robust antigen-
specific immune response and are highly effective as vaccine adjuvants for cancer 
immunotherapy. 
 
 
2.3. Materials and Methods 
2.3.1. Materials 
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The polymer poly(lactide-co-glycolide) (PLGA; 50:50 lactide-glycolide ratio; 
0.55-0.75 dl/g inherent viscosity) was purchased from Lactel (Birmingham, AL). TLR 7/8 
agonists (522 and 528) were synthesized and characterized as reported previously 42,75. 
Polyvinyl alcohol (PVA), 6-coumarin, ammonium acetate and albumin from chicken egg 
white (ovalbumin, OVA) were purchased from Sigma-Aldrich (St Louis, MO). Chloroform 
and acetonitrile were purchased from Fisher Scientific (Rockford, IL). Carboxyfluorescein 
succinimidyl ester (CFSE) Cell Division Tracker Kit was purchased from Biolegend (San 
Diego, CA). 
Fluorophore-labeled monoclonal antibodies were purchased from Biolegend (San 
Diego, CA) (CD3, CD8, CD11c, CD80, IFN-γ), eBioscience (San Diego, CA) (CD4, 
CD44, CD11a, CD40, CD86) and Tonbo Biosciences (San Diego, CA) (I-A/I-E(MHC II)). 
Fluorophore labeled H-2Kb OVA257-264 (SIINFEKL) tetramer was provided by Dr. Dave 
Masopust (University of Minnesota). 
 
2.3.2. Methods 
Animals and cell lines 
 C57BL/6 mice (6-8 weeks, female) and Balb/c mice (7-8 weeks, female) were 
purchased from Charles River (Wilmington, MA) and National Cancer Institute (Frederick, 
MD), respectively. Mice were housed under specific pathogen free (SPF) facilities in 
Research Animal Resources at the University of Minnesota. All animal experiments were 
performed according to the protocols approved by Institutional Animal Care and Use 
Committee (IACUC) of the University of Minnesota. 
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Ovalbumin expressing murine melanoma cell line B16F10-OVA was provided by 
Dr. Brandon Burbach (University of Minnesota). Murine bladder cancer cell line MB49 
was purchased from ATCC. B16F10-OVA and MB49 cells were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum, 100 μg/mL streptomycin and 100 
U/mL penicillin. G-418 Disulfate (Research products international, Mt Prospect, IL) was 
added to the medium when culturing B16F10-OVA (5 μg/mL). Murine kidney 
adenocarcinoma Renca cell line that stably expresses firefly luciferase and green 
fluorescent protein (GFP) (Renca-GL) was obtained from Dr. Andrew Wilber (Southern 
Illinois University School of Medicine, Springfield, IL). Renca-GL cells were maintained 
in RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, sodium pyruvate, 
nonessential amino acids, and HEPES (hereafter referred to as complete RPMI) medium 
supplemented with 0.3 μg/ml puromycin and 300 μg/ml zeosin. 
 
Fabrication and characterization of TLR agonist-loaded PLGA nanoparticles  
The TLR7/8 agonist 522 (or 528) loaded PLGA nanoparticles (522NPs or 528NPs) 
were fabricated using the oil-in-water emulsion solvent evaporation method 78,79. Briefly, 
2.5% w/v PVA was prepared in endotoxin-free distilled water (D.I. water) and used as the 
aqueous phase. The oil phase was prepared by dissolving 1.5 mg of 522 and 50 mg of 
PLGA in 2 ml of chloroform. This solution was added to 8 ml of 2.5% PVA, and the mix 
was sonicated for 5 min using probe-sonicator (Sonicator XL, Misonix, Melville, NY) to 
form an emulsion. This emulsion was stirred for ~18 h under ambient conditions, followed 
by an additional 1 h in a desiccator under vacuum. Nanoparticles were separated by 
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centrifugation (Optima XPN-80 Ultracentrifuge, Beckman Coulter Inc., Fullerton, CA) 
(35,000 RPM, 35 min) and then resuspended in D.I. water. The procedure was repeated 
two additional times to remove unencapsulated agonist and residual PVA. Nanoparticles 
were then lyophilized (Labconco FreeZone 4.5, Kansas City, MO), and stored at -20°C 
until further use. 
Size and zeta potential of nanoparticles were measured by dynamic light scattering 
(DLS) (DelsaTM Nano C, Beckman Coulter Inc.). One milligram of nanoparticles was 
dispersed in D.I. water and sonicated before measurements. Morphology of nanoparticles 
was imaged using transmission electron microscope (TEM) (FEI Tecnai G2 F30) and 
scanning electron microscope (SEM) (Hitachi SU8230, Hitachi). 
 
Agonist encapsulation and in vitro release  
To determine the amount of agonist loaded in the nanoparticles, methanol was 
added to 1 mg of nanoparticles to extract the agonist from the PLGA matrix. Extracted 522 
or 528 was quantified using high-performance liquid chromatography (HPLC; Beckman 
Coulter). Separation was achieved using a 50:50 mixture of ammonium acetate buffer (pH 
4) and acetonitrile as the mobile phase, run at an isocratic flow rate of 1 ml/min through 
Eclipse C-18 reverse-phase HPLC column (Agilent, 4.6 x 150 mm, particle size 4 µm). 
The agonists were detected and quantified using a fluorescence detector (Jasco Inc, Easton, 
MD; λex: 260 nm, λem: 340 nm). 
In vitro release of 522 from NPs was determined using a previously reported 
dialysis technique 82. Nanoparticles (2 mg/ml) were dispersed in release buffer (PBS, pH 
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7.4) and transferred to Float-A-Lyzer® dialysis tubes (molecular weight cut-off 20 kDa, 
Pierce). Dialysis tubes were immersed in release buffer (6 ml) contained in a 15-ml plastic 
tube. Sample tubes were incubated in a water bath shaker (Thermo scientific) at 37°C at 
100 RPM. At pre-determined time points, release buffer was collected and sample tubes 
were refilled with fresh release buffer. Collected samples were lyophilized, 522 was 
extracted with methanol and quantified by using HPLC as described above. 
 
PBMC isolation and stimulation 
Human PBMCs were isolated from heparinized blood obtained by venipuncture 
from healthy donors using standard density-gradient centrifugation over Ficoll-Plaque Plus 
(Pharmacia, Uppsala, Sweden). PBMCs (5 x 105 cells/1 ml/well in a 24-well plate) were 
cultured in complete RPMI medium. Soluble 522 was prepared in DMSO (hereafter 
referred to as Free522) and 522NP was prepared in complete RPMI. Free522 and 522NPs 
were added to the wells (in triplicate) so that the final concentration was between 50 μM 
and 0.39 μM. Some wells received only DMSO. After 24 h, culture supernatants were 
collected and frozen at -80°C until analysis. The concentration of cytokines in the 
supernatants was determined by using ELISA (BioLegend).  
For cytotoxicity assay, PBMCs (2 x 104 cells/well in a 96-well plate) were 
incubated with 522NPs (15.6 ~250 μg/ml, equal to 0.47 ~ 7.5 μM of 522), Free522 (0.47 
~ 7.5 μM) for 48 h. After 48 h, culture supernatants were collected. Cytotoxicity of the 
treatments was measured according to the manufacturer’s protocol (LDH Cytotoxicity 
Assay Kit, Thermo). 
  24 
 
TLR7 and 8 reporter cell assay 
Human TLR-specific reporter cell assays were carried out as previously reported 
75. Briefly, reporter cells (HEK-BlueTM-hTLR7 and 8, InvivoGen, San Diego, CA) were 
seeded at 40,000 cells per well in 96-well cell culture plate. After 24 h, imiquimod, Free522 
and 522NPs were prepared in DMEM media (25 μM) and added to the reporter cells. The 
supernatants were collected the following day for colorimetric assay. 
 
Culture of bone marrow-derived dendritic cells (BMDCs) 
BMDCs were produced using established protocols with modifications 83. Briefly, 
tibias and femurs from C57BL/6 mice were harvested, disinfected with 70% ethanol, and 
rinsed twice with cold PBS (pH 7.4). Both ends of the bones were cut, and bone marrow 
precursor cells were flushed with PBS using a 27-gauge needle (Medtronic, Minneapolis, 
MN). The flushed bone marrow was filtered using a 70-micron nylon mesh, and 
erythrocytes were removed using lysis buffer (Pharm Lyse, BD Bioscience, San Jose, CA). 
Single cell suspension of bone marrow precursor cells was added to a petri dish and 
incubated with complete RPMI 1640 media supplemented with 20 ng/mL granulocyte-
macrophage colony-stimulating factor (GM-CSF) (PeproTech, Rocky Hill, NJ) and 50 μM 
2-mercaptoethanol (Sigma) for 6 d to generate immature BMDCs. Media was changed 
once on day 3. 
 
Cellular uptake and intracellular trafficking of nanoparticles in BMDCs 
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6-coumarin, a hydrophobic fluorescent dye, was co-encapsulated with 522 to label 
nanoparticles (C6NPs). The fabrication of C6NP was identical to that of 522NPs, except 
for the addition of 700 µg of 6-Coumarin to the organic phase. For in vitro cellular uptake 
study, BMDCs (106/well) were seeded in a 24-well cell culture plate. The following day, 
C6NPs (0.2 mg/ml) were added to BMDCs and incubated for 2 h. Cells were detached 
using non-enzymatic cell dissociation solution (Sigma-Aldrich) and rinsed twice with PBS, 
followed by staining with anti-CD11c mAb. Cellular uptake of C6NPs by BMDCs was 
determined by monitoring the 6-coumarin-associated fluorescence signal in the CD11c+ 
cells by flow cytometry (BD LSR II, BD Biosciences, San Diego, CA). 
Intracellular distribution of C6NPs was determined by confocal laser scanning 
microscopy (Olympus FluoView FV1000 BX2 Upright Confocal, Olympus, Center 
Valley, PA). BMDCs (5000/chamber) were seeded into a Lab-Tek® Chamber Slide™ 
system (Sigma). The next day, the BMDCs were incubated with C6NPs (0.1 mg/ml) for 2 
h, and then rinsed with PBS twice. Cells were stained with LysoTracker® Red DND-99 
(Thermo scientific) and fixed with 3% paraformaldehyde (PFA), followed by staining with 
4',6-diamidino-2-phenylindole (DAPI; Thermo scientific). Confocal images were further 
analyzed by Olympus Fluoview viewer 2.0 software. 
 
In vitro BMDC activation and antigen presentation   
BMDCs (106/well) were seeded in a 24-well cell culture plate. Following 
attachment, Blank NPs (PLGA nanoparticles without any TLR agonist, 50 µg/ml), 522NPs 
(50 µg /ml, equivalent to 50 ng/ml of Free522) or Free522 (50 ng/ml) were added to each 
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well. After 24 h, BMDCs were collected and analyzed for co-stimulatory molecule (CD40, 
CD86, and CD80) expression by flow cytometry. To assess antigen presentation, OVA (30 
µg) was co-incubated with treatment groups. After 24 h, BMDCs were collected and 
stained with anti-OVA257-264 (SIINFEKL) peptide bound to H-2K
b-APC (eBioscience) 
antibody and analyzed by flow cytometry to detect DCs presenting OVA-specific peptides 
via MHC I. 
 
In vivo distribution of nanoparticles 
C6NPs (2.6 mg/mouse) were injected subcutaneously in the flank of C57BL/6 
mice. Mice were sacrificed at 1 h and 6 h, and inguinal lymph nodes, liver, kidney, spleen, 
heart and lung were collected. Harvested organs were homogenized in D.I. water using the 
Omni Tissue Homogenizer (OMNI, Kennesaw.GA) and lyophilized. 6-coumarin was 
extracted from lyophilized samples with diethyl ether and methanol, and quantified using 
HPLC 84. To measure extraction efficiency, organs were harvested from untreated mice 
and homogenized with a known amount of 6-coumarin and processed identical to the 
samples. Extraction efficiencies for each of the organs is presented in Table 2.2 
For lymph node imaging, mice were sacrificed 6 h after injection, and inguinal 
lymph nodes were collected, embedded in Tissue-Tek® OCT compound (Sakura Finetek 
USA, Inc.) and frozen at -80°C. Frozen lymph node sections (5 µm thick) were mounted 
on glass slides, stained with anti-CD11c-AF700 antibody to label DCs, and imaged by 
confocal microscopy. 
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Immunization protocol 
C57BL/6 mice were immunized daily for 5 d with OVA (100 µg) admixed with 
Free522 (2 µg) or 522NPs (2 mg; equivalent to 2 µg of Free522) dispersed in 200 µl of 
sterile PBS. For TRP immunization, 100 µg of TRP-2 peptide (180-188) was used. Each 
dose was divided into two 100 µl subcutaneous injections, administered to the left and right 
thighs.  
For tumor cell lysate vaccine formulation, MB49 cell lysate was prepared by five 
cycles of freeze (liquid nitrogen)-thaw (56°C water bath). Cell debris was pelleted down 
and the protein concentration of the supernatants was measured using Pierce™ BCA 
Protein Assay Kit (Thermo). Cell debris pellets were reconstituted with supernatants. 
Free522 (2 µg) or 522NPs (2 mg) and 100 µg of the cell lysate were mixed with 200 µl of 
sterile PBS to create the vaccine. Vaccination schedule and injection sites were identical 
to those used for OVA immunization. 
 
In vivo DC and T cell proliferation assay 
C57BL/6 mice were immunized as described above. For DC analysis, four groups 
were used: untreated, OVA alone, OVA+Free522 and OVA+522NP. For T cell 
proliferation assays, a group of mice receiving 522NP without OVA (522NP only) group 
replaced the OVA+Free522 group. Mice were euthanized 2 d after the final dose (d 8). For 
T cell proliferation assay, 100 µg of OVA257-264 peptide was injected intravenously to each 
mouse on the day of harvest. Mice were euthanized and organs were harvested 4 h after 
the peptide injection. 
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A single cell suspension of lymph nodes and spleen was prepared following an 
established protocol 45. Briefly, lymph nodes and spleens were mechanically homogenized 
using gentleMACS Dissociator (Miltenyi BioTeck Inc., Auburn, CA). Homogenized cell 
suspension was then digested in Hanks' Balanced Salt solution (HBSS) supplemented with 
0.15 mg/ml DNAse I (Sigma) and 0.56 Wuensch units/ml Liberase Blendzyme 3 (Roche, 
Branford, CT). After 30 min, erythrocytes were removed using lysis buffer, and cells were 
blocked with anti-CD16/32 (Tonbo) and normal mouse serum. Cells were stained to 
identify DCs and T cells, and analyzed using flow cytometry. For DCs, the following 
antibodies were used: anti-CD11c-APC Cy7, I-A/I-E (MHC II) -vF450, CD40-PE, CD86-
FITC, and CD80-PE Cy5. For T cells, the following antibodies were used: CD3-PerCP 
Cy5.5, CD4-PE Cy7, CD8-BV650, CD44-AF700, OVA257-264:H-2K
b Tetramer-APC, and 
IFN-γ-BV605. Intracellular staining of IFN-γ was performed according to the 
manufacturer’s protocol (Foxp3/Transcription Factor Staining Buffer Set, eBioscience). 
Counting beads (eBioscience) were used to calculate cell numbers. Acquired data was 
analyzed using FlowJo software (TreeStar Inc., Ashland, OR). 
 
In vivo cytotoxic T lymphocyte (CTL) assay 
C57BL/6 mice were immunized as described above and an in vivo CTL assay was 
conducted two days after the final vaccination (d 8). Splenocytes from naïve C57BL/6 mice 
were pulsed with either 2 µg/ml of OVA257-264 peptide or PBS for 1 h in 37°C. OVA257-264 
pulsed cells and PBS incubated cells were stained with 7 µM and 0.7 µM CFSE, 
respectively, for 20 min. Equal numbers (5x106 each, total 107) of CFSEhigh (OVA257-264 
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pulsed, “Target”) and CFSElow (unpulsed, “Control”) cells were mixed in 100 µl PBS and 
injected intravenously in the immunized mice. On d 9, splenocytes of the immunized mice 
were analyzed by flow cytometry for CFSE+ population. CFSElow:CFSEhigh cell ratio was 
calculated to determine the percentage of in vivo OVA-specific lysis. 
 
In vivo tumor models 
In prophylactic studies, C57BL/6 mice were immunized as described above. For 
metastatic lung tumor model, B16F10-OVA cells (1 x 105 in 100 µl PBS) were injected 
intravenously through the tail vein on d 8. Lungs were collected on d 26 and number of 
tumor foci on each lung was counted under SMZ-2T trinocular stereoscope (Nikon). On a 
different set of similarly treated animals, spleens were harvested on d 13 and T cells were 
analyzed by flow cytometry. For subcutaneous tumor model, B16F10-OVA cells (5 x 105 
in 100 µl PBS) or MB49 cells (1.5 x 105 in 100 µl PBS) were inoculated subcutaneously 
near the abdominal region on d 8.  
In therapeutic studies, B16F10-OVA cells (2 x 105 in 100 µl PBS) or MB49 cells 
(1.5 x 105 in 100 µl PBS) were inoculated subcutaneously near the abdominal region of 
C57BL/6 mice. Once tumors were palpable, mice were immunized as described above. 
Subcutaneous tumor size was measured using digital calipers (Thermo Fisher Scientific). 
Tumor volume was calculated as V = 0.5 x (L x W2) (L: longest diameter, W: shortest 
diameter). Mice with tumor volume greater than 2000 mm3 or those that developed tumor 
ulceration were removed from the study and euthanized.  
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In situ vaccination in an orthotopic kidney tumor model 
For intrarenal (IR) tumor challenge, Balb/C mice were anesthetized, a skin incision 
was made on the left flank, and 2 × 105 Renca-GL cells were injected through the intact 
peritoneum into the left kidney in a 100 μl volume of HBSS 45,85. On d 7, mice were re-
injected in the same kidney with sterile PBS, Ad5-TRAIL (109 pfu), and/or Free528 (1 µg) 
or 528NPs (1mg, equivalent to 1 µg of Free528) in a 100 μl volume. Renal tumor growth 
and lung metastasis burden were measured via bioluminescence imaging using a Xenogen 
IVIS Spectrum (PerkinElmer, Waltham, MA). Mice were intraperitoneally (I.P.) injected 
with 100 μl of D-Luciferin (Goldbio, St. Louis, MO) (15 μg/ml) 10 min before imaging. 
Renca-GL generated radiance (photons/s/cm2) was quantified within a region of interest 
using Living Image software (Version 2.5). For end time-point experiments, lungs were 
harvested on d 21 and renal tumor burden was measured via BLI. 
 
Statistical analyses 
Results were reported as mean ± standard deviation (SD) or mean ± standard error 
of the mean (SEM). One-way analysis of variance (ANOVA), with a post hoc Tukey test 
was used to examine the statistical difference between the groups, unless otherwise stated. 
Data was analyzed with Prism4 GraphPad software (GraphPad Software, La Jolla, CA). A 
p-value <0.05 was considered statistically significant. 
 
2.4. Result 
2.4.1. 522 activates TLR7 and 8 pathways 
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In our initial experiments, we wanted to demonstrate the specificity and potency of 
the canonical TLR7 agonist imiquimod and our new imidazoquinoline-based agonist 522 
(Figure 2.1A). To assess specificity, reporter cell assays were used to examine ability of 
imiquimod and 522 to stimulate TLR7 or TLR8 relative to that of imiquimod. Using 
identical concentrations of each agonist, we saw both imiquimod and 522 could stimulate 
TLR7 signaling, but 522 showed significantly enhanced TLR7 activity compared to 
imiquimod (Figure 2.1B). Moreover, only 522 was able to stimulate TLR8. 
One characteristic outcome of TLR engagement is the production of cytokines 73. 
We next examined the ability of imiquimod and 522 to stimulate cytokine production from 
human PBMCs in vitro. Consistent with previous data 75, human PBMCs stimulated with 
522 produced significantly greater concentrations of IL-1, IL-12p70, IFN-γ, and TNF-α 
over imiquimod (Figure 2.1C). These data show the dual specificity of 522 results in a 
much stronger pro-inflammatory cytokine production by PBMC compared to the TLR7-
specific agonist imiquimod.  
 
 
 
(A)                                                                                        
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(C)  
 
Figure 2.1.  522 is a dual TLR 7/8 agonist  
(A) Structures of prototypical TLR7 selective compound imiquimod and dual TLR7/8 
agonist 522. (B) Human TLR7 or TLR8 specific reporter cells were incubated with 
imiquimod or 522 for 24 h. TLR specific activity is measured by SEAP activity at OD650. 
Results are reported as mean  SD, n=4, **p<0.01, ***p<0.001, n.s.=not significant, One-
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way ANOVA. (C) Human PBMCs were incubated with imiquimod or 522 for 24 h and IL-
1, IL-12p70, IFN-, and TNF-were measured by ELISA. Results are reported as mean 
 SD, n=3. 
 
2.4.2. Physicochemical characterization and in vitro release profile of 522NPs 
Nanoparticle characteristics are highly dependent on the materials and parameters used 
during fabrication 54. The 522NPs were spherical in shape (Figure 2.2A) and had an 
average diameter of 156 ± 26 nm as determined by scanning electron microscopy (Figure 
2.2B). This size range was consistent with the hydrodynamic size measured by DLS (Table 
2.1). Nanoparticles were negatively charged, with an average zeta potential of –16.4 ± 1.2 
mV. 528NPs had similar particle size, surface charge and drug loading characteristics as 
the 522NPs (Table 2.1). In vitro release studies revealed the nanoparticles released ~40% 
of their payload within the first 24 h, followed by a slower release over the next 200 h in 
pH 7.4 buffer (Figure 2.2C). LDH assay using human PBMC confirmed both 522NPs and 
Free522 have negligible cytotoxicity against primary cells (Figure 2.2D). To determine 
the extent to which 522 maintains its activity after encapsulation in PLGA nanoparticles, 
TLR reporter cell and PBMC stimulation assays were conducted. 522NPs maintained 
TLR7 and 8 activity and were able to induce IFN- secretion from PBMCs to a similar 
extent as Free522 (Figure 2.2E,F). 
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 (C)                                                                                     (D)  
  
(E)                                                                                                                           (F)  
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Figure 2.2.  522NP in vitro release profile and in vitro efficacy  
(A) A representative TEM image of 522NPs. Scale bar, 50 nm. (B) A representative SEM 
image of 522NPs. Scale bar, 200 nm.  (C) Cumulative release of 522 from PLGA 
nanoparticles in pH 7.4 PBS. Results are reported as mean  SD, n=3. (D) Cytotoxicity of 
522NPs and Free522 against PBMCs. Treatments were incubated with PBMC for 48 h and 
LDH assay was conducted to measure cytotoxicity. Results are reported as mean  SD, 
n=4. (E) Human TLR7 or TLR8 specific reporter cells were incubated with DMEM, 
Free522 and 522NP for 24 h. TLR specific activity was measured by SEAP activity at 
OD650. Results are reported as mean  SD, n=3, ***p<0.001, One-way ANOVA. (F) 
Human PBMCs were incubated with DMSO, Free522 and 522NP for 24 h and IFN- was 
measured by ELISA. Results are reported as mean  SD, n=3. 
 
 
 
Table 2.1. Physiochemical characterization of 522NPs and 528 NPs  
Particle size, zeta-potential and polydispersity index of 522NPs and 528NPs  were 
measured by DLS. Amount of 522 or 528 loaded in nanoparticles was quantified using 
HPLC. Results are reported as mean  SD, n=3. 
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2.4.3. Uptake of nanoparticles by BMDCs and the effects of nanoparticle delivered 
522 
 Unencapsulated TLR agonists are well known for their ability to stimulate their 
cognate TLR, while encapsulation into nanoparticles (such as the PLGA-based 
nanoparticles using herein) can delay/prevent degradation, improve cellular uptake, and/or 
serve as a depot for prolonged release. Thus, we next examined the interaction between 
BMDCs with nanoparticles and the consequences of NP-mediated delivery of 522 
compared to Free522. Following incubation with fluorescently labeled 522NPs, the entire 
population of CD11c+ BMDCs increased in fluorescence (Figure 2.3A), suggesting 
BMDCs efficiently internalize 522NPs. To further confirm the nanoparticles were indeed 
internalized by BMDCs and investigate the intracellular localization of nanoparticles, 
BMDCs incubated with nanoparticles were fixed and imaged using confocal microscopy 
after staining with DAPI (blue) and lysotracker (red) to visualize the nucleus and acidic 
endo/lysosomes, respectively. The majority of nanoparticles were localized in the 
endo/lysosomes (shown by the presence of yellow fluorescence in the merged picture) and 
a small fraction of the internalized nanoparticles was found in the cytosol (Figure 2.3B). 
These data show 522NPs can be internalized efficiently by BMDCs and reach the 
endo/lysosomes where TLR7 and 8 are located 86. 
We next examined the extent to which 522, soluble or encapsulated within NPs, 
can activate BMDCs. BMDCs were incubated alone or with Blank NP, Free522, or 522NP 
for 48 h, and then evaluated for CD40, CD80, and CD86 expression. While BlankNP did 
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not alter co-stimulatory molecule expression on BMDCs compared to unstimulated cells, 
there was a significant increase in the frequency of cells expressing CD40, CD80, or CD86 
after exposure to either Free522 or 522NPs (Figure 2.3C). Just as co-stimulatory molecule 
expression (“signal 2”) by antigen-presenting cells is needed for proper T cell activation 
87, adequate expression of antigenic peptides within the context of MHC is required for 
antigen-specific T cell activation 88. Thus, we examined the expression of the well-known 
OVA-derived MHC I-restricted epitope SIINFEKL on BMDCs incubated with whole 
OVA alone, or in combination with Free522 or 522NPs 89. In contrast to the nearly identical 
increase in co-stimulatory molecule expression after exposure to either Free522 or 522NPs, 
the frequency of BMDCs expressing the SIINFEKL:MHC I complex was significantly 
increased after stimulation with 522NPs (Figure 2.3D). These results suggest the greatest 
potential for T cell activation occurs with the combination of antigen and agonist loaded 
NPs.  
 
 
 
 (A) 
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(C)                                                                                                                                                                    
                
 
 
(D)      
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Figure 2.3.  BMDC internalization and activation 
(A) BMDCs were incubated with C6NPs for 2 h and fluorescence intensity of BMDCs was 
then measured by flow cytometry. A representative histogram for each of the groups (n=3) 
is shown. (B) A representative confocal image of BMDCs treated with C6NPs (Green: 
Nanoparticles, Red: Endo/lysosome). Merged signals are shown in yellow and highlighted 
with arrows. Scale bar, 5 µm. (C) Flow cytometry analysis of CD40, CD80 and CD86 
expression on BMDCs after 48 h incubation with 522 treatments. Results are reported as 
mean  SEM, n=3, ***p<0.001, One-way ANOVA. (D) BMDCs were incubated with 
OVA and/or 522 treatments for 48 h. Flow cytometry analysis of BMDCs expressing 
OVA257-264 (SIINFEKL) peptide bound to H-2K
b are shown. Results are reported as mean 
 SEM, n=3, ***p<0.001, One-way ANOVA. 
 
 
2.4.4. Nanoparticle migration to lymph node  
To efficiently activate DCs in vivo, it is crucial for 522NPs reach the lymphoid 
organs including lymph nodes and spleen where a majority of DCs are located 65. Following 
S.C. injection, nanoparticles were detected in all organs 1 h later and showed a slight 
increase at 6 h (Figure 2.4A). Inguinal lymph nodes, which drain the subcutaneous 
injection site, showed the highest distribution of nanoparticles. These results suggest S.C. 
injected nanoparticles enter both the lymphatic and systemic circulation efficiently. 
Accumulation of 522NPs in the draining lymph node was further examined by 
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immunofluorescence imaging. Nanoparticles were tracked using their green fluorescence 
and DCs were labeled with an anti-CD11c antibody. Nanoparticles were evenly distributed 
in the lymph node (Figure 2.4B), and merged signals indicate co-localization of 
nanoparticles and DCs. Although we could not distinguish DCs that internalized 
nanoparticles at the injection site and migrated to lymph nodes from lymph node resident 
DCs, our data demonstrate 522NPs can access the DCs in the lymph node. 
Initiation of an immune response can be determined by DC expansion and activation in 
lymph nodes 90. As our results showed 522NPs drain to lymph nodes and co-localize with 
DCs, we next examined the extent to which 522NP vaccination triggered DC expansion 
and activation in vivo. Mice were vaccinated with a model antigen OVA, and inguinal 
lymph nodes were collected to measure the number of total DCs and co-stimulatory 
molecule expressing DCs. We found the total number of DCs in lymph node of mice 
vaccinated with OVA+522NP increased 3- and 1.5-fold compared to those in the untreated 
and OVA only treated groups, respectively (Figure 2.4C). DCs expressing co-stimulatory 
molecules CD40, CD86 and CD80 were significantly higher in the OVA+522NP 
vaccinated mice compared to those in the untreated and OVA-only treated groups. These 
data demonstrate the inclusion of 522NP in the vaccine enhances DC maturation in lymph 
nodes, a key step in priming T cells. 
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Figure 2.4.  522NPs migrate to draining lymph node and mature DCs 
(A) C6NPs were injected S.C. and organs were harvested 1 and 6 h later. The amount of 
6-coumarin in different organs was quantified by HPLC. (B) Inguinal lymph nodes were 
collected 6 h after S.C. injection of C6NPs and processed for immunofluorescence. A 
representative confocal image of the inguinal lymph node is shown. Green signal indicates 
location of C6NPs and red signal indicates CD11c+ cells. Orange signals from merged 
image indicate co-localization of C6NPs and CD11c+ cells. Images were taken at 10X and 
60X magnification. Scale bar, 200 µm (10X), 20 µm (60X). (C) Inguinal lymph nodes were 
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harvested on d 7 after 5 doses of OVA vaccination. CD11c+/MHC II+ cells were gated as 
DCs and numbers of total DCs, CD40high, CD86high and CD80high cells were counted. 
Results are reported as mean  SEM, *p<0.05, **p<0.01, ***p<0.001, n=3~4, one-way 
ANOVA. 
 
 
 
Table 2.2. Extraction efficiency of C6NPs  
Mouse organs were harvested and processed with 1 µg of 6-coumarin. Amount of 6-
coumarin per organ was measured by HPLC. Extraction efficiency was calculated by 
(amount extracted (µg) / 1 µg ) x 100.  Results are reported as mean  SD, n=3~4. 
 
 
2.4.5. 522NP vaccination generates antigen-specific effector CD8 T cells 
We next investigated the extent to which vaccination with 522NPs activated T cells. 
Since we were using OVA as the model antigen, we were in the position to examine the 
priming of OVA-specific CD8 T cells using the OVA257-264:H-2K
b tetramer 91. We first 
measured the overall expansion of OVA257-264-specific CD8 T cells, and found 4.5-fold and 
3-fold more in OVA+522NP vaccinated mice than in untreated and OVA only treated 
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groups, respectively (Figure 2.5A). One of the key functions of effector CD8 T cells is the 
production of IFN-γ 92. We measured IFN-γ secretion by OVA-specific CD8 T cells after 
stimulating the vaccinated mice with OVA257-264 peptides, and found OVA+522NP 
vaccinated mice showed the highest number of OVA257-264-specific IFN-γ+ CD8 T cells 
(Figure 2.5B). Expansion of overall and effector OVA-specific CD8 T cells in 
OVA+522NP vaccinated mice demonstrates the DCs matured by 522NPs are able to 
efficiently process and present the antigens to generate Ag-specific effector CD8 T cells. 
Effector CD8 T cells have the ability to directly kill target cells with granule 
exocytosis and death ligand expression 93. To assess the efficacy of 522NP vaccination in 
inducing antigen-specific, CTL-mediated cell lysis, an in vivo CTL assay was conducted. 
The ratio of control cells (unpulsed, CFSElow) to target cells (OVA257-264 pulsed, CFSE
high) 
(C:T ratio) in the untreated group was 1.1, which indicates negligible target cell specific 
lysis (Figure 2.5C). The C:T ratio of OVA+522NP vaccinated mice was 9.01. OVA- and 
522NP-only groups had C:T ratios of 2.5 and 1.3, respectively (Figure 2.5D). We then 
calculated the percent specific lysis using the C:T ratios. Mice immunized with 
OVA+522NP showed 87% Ag-specific lysis, suggesting OVA+522NP generated CD8 T 
cells can selectively find and kill the target cells (Figure 2.5E). In contrast, OVA only 
treated group and 522NP only treated group each showed 52% and 12% specific lysis, 
respectively. The lower percent specific lysis in the OVA only and 522NP only groups 
suggest either the antigen or adjuvant alone is insufficient to induce a strong antigen-
specific CTL response. 
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Figure 2.5.  T cell expansion and CTL activity 
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(A,B) T cell expansion - Spleens of immunized mice were collected and analyzed using 
flow cytometry. The number of CD8+ T cells were calculated using counting beads. (A) 
Number of OVA257-264-specific CD44
high CD8 T cells (B) Number of OVA257-264-specific  
IFN-γ+ CD8 T cells. Results are reported as mean  SEM, *p<0.05, **p<0.01, n=3~4, one-
way ANOVA. (C-E) CTL assay - Splenocytes labeled with CFSE were injected into 
immunized C57BL/6 mice. After 24 h, spleens were harvested for flow cytometry analysis. 
Only CFSE+ cells are shown. (C) Representative flow cytometry plots for OVA257-264-
pulsed (CFSEhigh, target cells) and unpulsed splenocytes (CFSElow, control cells). (D) Ratio 
of number of CFSElow splenocytes (C) to CFSEhigh splenocytes (T) in the spleen of the 
immunized mice. (E) Percent specific lysis of OVA257-264-pulsed splenocytes is shown. 
Results are reported as mean  SEM, ***p<0.001, n=4, one-way ANOVA. 
 
2.4.6. B16F10-OVA lung metastasis and subcutaneous model  
All of the data obtained thus far showing potent priming of CD8 T cells using 
522NPs led us to examine the therapeutic efficacy of 522NPs using a variety of 
immunization protocols in different tumor models. We first investigated the prophylactic 
and therapeutic efficacy of OVA+522NP vaccination in mice bearing B16F10-OVA 
tumors 94. Prophylactic efficacy of OVA+522NP was initially investigated in a lung 
metastasis model. Untreated and OVA+Free522 vaccinated mice had numerous lesions in 
the lung, while OVA+522NP immunized mice had relatively clear lungs (Figure 2.6A) 
with significantly fewer tumor modules (Figure 2.6B). Further, OVA+522NP immunized 
mice had 7- and 2.5-fold higher number of Ag-specific CD8 T cells compared to the 
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untreated and OVA+Free522 treated mice, respectively (Figure 2.6C). These results 
suggest the significantly increased number of Ag-specific CD8 T cells in OVA+522NP 
immunized mice protected them against the massive lung metastasis seen in the control 
groups. 
Prophylactic efficacy of OVA+522NP immunization was also investigated in a S.C. 
tumor model where the tumor growth mimics human primary melanoma 95. Palpable 
tumors were detected in all groups except OVA+522NP treated mice on d 10. In untreated 
group, tumors grew rapidly and reached a volume of 1000 mm3 by d 21. OVA only, 
OVA+Free522 and 522NP only groups also demonstrated similar tumor growth trends 
(Figure 2.6D). On the contrary, OVA+522NP vaccinated mice developed palpable tumors 
on d 14 and only two mice in the group (n = 6) had established tumors on d 21. At the end 
of the study, OVA+522NP vaccinated mice had significantly slower tumor growth and 
100% survival. Data from both the lung metastasis and S.C. melanoma models suggest 
OVA+522NP prophylactic vaccination induces strong protective immune response against 
the B16F10-OVA cells and can delay the tumor growth significantly. We next examined 
the efficacy of OVA+522NP immunization against established tumors. The B16F10-OVA 
tumors were palpable by d 13 and mice were immunized for five days (d 13-17). Up to d 
25, all the groups showed similar tumor growth trends. However, OVA+522NP immunized 
started to show reduced tumor growth on d 28 compared to the other treatment groups 
(Figure 2.6E). It takes 7-10 days to generate antigen-specific T cells after immunization 
96, which is identical to the time point where OVA+522NP therapy became effective. 
  48 
OVA is a foreign antigen and highly immunogenic 97, prompting us to investigate 
the extent to which immunization with 522NP will generate anti-cancer immune response 
with endogenous tumor antigens, which can be less immunogenic and more challenging to 
elicit a protective T cell response. As we are using B16F10 cells in these experiments, we 
took advantage of the immunizing with the tyrosine related protein 2 (TRP-2), an 
endogenous antigen expressed on B16F10 cells 77,97. In this study, B16F10 tumors were 
palpable on d 15 and mice received 5 vaccination doses (d 15-19). TRP-2 + Free522 
immunized mice showed slight tumor inhibition by d 28, but aggressive growth was 
observed on d 31 (Figure 2.6F). On the other hand, TRP-2 + 522NP immunized mice 
showed delayed tumor growth up to d 31. Consistent with OVA immunization, TRP-2 + 
522NP immunization became effective ~10 days after the final dose. These results suggest 
522NP immunization can induce both prophylactic and therapeutic immunity when co-
administered with tumor-specific antigen. 
 
(A)                                                                                             
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Figure 2.6.  Tumor challenge using B16F10-OVA melanoma tumor models  
(A-C) Lung metastasis model - C57BL/6 mice were immunized and B16F10-OVA cells 
were injected intravenously to establish lung tumors. (A) Images of lungs harvested on d 
28 after cell injection (B) Number of lung tumor metastases were counted using a trinocular 
stereoscope. Results are reported as mean  SEM, ***p<0.001, n=4, one-way ANOVA. 
(C) A different cohort of animals were treated as in (A) and spleens were harvested on d 
13 and OVA257-264 -specific CD44
high CD8 T cells were counted. Results are reported as 
mean  SEM, **p<0.01, ***p<0.001, n=4~5, one-way ANOVA. (D-F) S.C. tumor model 
- (D) C57BL/6 mice were immunized (d 1-5) and B16F10-OVA cells were injected 
subcutaneously to establish the tumor on d 8. Average volumes of tumors are shown. 
Results are reported as mean  SEM; statistical analysis indicates Untreated Vs 
OVA+522NP groups, *p<0.05, **p<0.01, ***p<0.001, n=6, Repeated-measures ANOVA 
with posthoc Bonferroni test. (E) B16F10-OVA cells were inoculated on d 0 and treatments 
were given for five days (d 13-17). Results are reported as mean  SEM; statistical analysis 
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indicates Untreated Vs OVA+522NP groups, **p<0.01, ***p<0.001, n=7~9, Repeated-
measures ANOVA with posthoc Bonferroni test. (F) B16F10-OVA cells were inoculated 
on d 0 and treatments were given for five days (d 15-19). Results are reported as mean  
SEM; statistical analysis indicates Untreated Vs TRP-2+522NP groups, ***p<0.001, 
n=5~6, Repeated-measures ANOVA with posthoc Bonferroni test. 
 
2.4.7. Whole tumor vaccine against MB49 tumors 
The above results suggest vaccination with 522NP induces antigen-specific CTL 
responses that effectively kill antigen-expressing tumor cells. However, tumor-specific 
antigens (e.g., RAS, BRAF, EGFR) are not available for all tumor types 98,99. Whole tumor 
cell lysate-based vaccines are a promising alternate modality that seeks to overcome some 
of the limitations associated with peptide-based vaccines 100. Therefore, we used a whole 
tumor cell lysate (CL) as the antigen source and investigated the effectiveness of 522NP to 
prime antitumor immunity when a non-peptide antigen source was used. For this purpose, 
we selected the immunogenic murine bladder cancer MB49 cell line as the antigen source 
101,102. We first examined the CD8 T cell response by determining the frequency of “Ag-
experienced” CD11ahiCD8lo CD8 T cells in the spleen 103. We found the frequency of 
CD11ahiCD8lo CD8 T cells increased when mice were vaccinated with CL+522NP, 
suggesting 522NP is able to enhance the immunogenicity of a tumor cell lysate and elicit 
a tumor-specific CD8 T cell response (Figure 2.7A). Prophylactic efficacy of CL+522NP 
was investigated against S.C. MB49 tumors. CL+522NP significantly delayed tumor 
growth compared to control groups (Figure 2.7B). On d 30, average tumor volumes 
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reached ~1000 mm3 in untreated mice and ~500 mm3 in CL alone and CL+Free522 treated 
groups. However, CL+522NP vaccinated mice showed remarkably very little tumor 
growth (~120 mm3) over the same time period. Moderately delayed tumor growth in CL 
alone and CL+Free522 mice indicates the MB49 CL with or without Free522 can provide 
sufficient antigens to trigger an immune response, but the maximal response was achieved 
only when 522NP was used as the adjuvant. In the therapeutic study, only CL+522NP 
treatment was effective in delaying tumor growth (Figure 2.7C). Unlike in the prophylactic 
study, where CL alone had a moderate effect, therapeutic effects were not observed from 
CL alone or CL+Free522 groups. We propose sustained release of 522 from nanoparticles 
allows for long-term generation of Ag-experienced (CD11ahiCD8lo) CD8 T cells, which 
leads to the observed efficacy of the CL+522NP treatment. 
 (A) 
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Figure 2.7.  Cell lysate vaccine efficacy against murine bladder cancer MB49 tumor 
models. 
(A) Number of CD11ahi/CD8lo CD8 T cells from spleens of MB49 cell lysate vaccine 
immunized mice. Results are reported as mean  SEM, *p<0.05, n=4, one-way ANOVA. 
(B) C57BL/6 mice were immunized (d 1-5) and MB49 cells were injected subcutaneously 
to establish the tumor on d 8. Results are reported as mean  SEM, Statistical analysis 
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indicates Untreated Vs CL+522NP groups,***p<0.001, n=5, Repeated-measures ANOVA 
with posthoc Bonferroni test. (C) MB49 cells were inoculated on d 0 and treatments were 
given for five days (d 8-12). Results are reported as mean  SEM, Statistical analysis 
indicates Untreated Vs CL+522NP groups,**p<0.01, n=5, Repeated-measures ANOVA 
with posthoc Bonferroni test. 
 
 
2.4.8. In situ vaccination in an orthotopic renal cell carcinoma (RCC) model 
In situ generated tumor cell lysates can be a rich source of tumor antigens to elicit 
anti-tumor immunity 104,105. Previously, our group reported in situ vaccine composed of 
adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) and 
TLR9 agonist CpG, which induced a robust CD8 T cell response, that resulted in 
eradication of both primary and metastatic RCCs 45,106. Therefore, we used Ad5mTRAIL 
to induce tumor ablation and investigated the extent to which nanoparticles encapsulating 
528 (528NPs) could augment systemic T cell immunity in this physiologically relevant 
orthotopic Renca tumor model. After a single intrarenal (IR) administration of treatments, 
whole body tumor burden was monitored by BLI. Consistent with previous studies, 
Ad5mTRAIL without immune stimulant treatment (Ad5mTRAIL + BlankNP) was not 
effective in reducing tumor growth. The tumor burden was significantly lower in mice 
immunized with Ad5mTRAIL + Free528 and Ad5mTRAIL + 528NP compared to other 
control groups, which demonstrates strong adjuvant capacity of 528 (Figure 2.8A). As 
tumor burdens from the primary tumor (kidney) and metastases could not be differentiated 
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based on whole body imaging, we excised the lungs and measured tumor-associated 
bioluminescence at the end of the study. Ex vivo imaging showed only Ad5mTRAIL + 
528NP was effective in reducing lung metastasis compared to the other control groups 
(Figure 2.8B). As CD8 T cells are known to play a key role in eradicating secondary 
lesions 107,108, these results suggest 528NP immunization can invoke persistent CTL 
response capable of reducing the growth of both primary and metastatic tumors. This is 
also consistent with our B16F10-OVA lung tumor model study where 522NPs induced 
protective immunity by expanding Ag-specific CD8 T cells. 
 
(A)  
 
(B) 
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Figure 2.8.  In situ vaccine against renal cell carcinoma 
Balb/c mice bearing IR Renca-GL tumors were treated with PBS alone or Ad5-TRAIL 
combined with BlankNP, Free528 or 528NP IR on d 7. (A) Whole body tumor burden was 
tracked with bioluminescent imaging. Results are reported as mean  SEM, Statistical 
analysis indicates Untreated Vs Ad5-TRAIL +528NP groups, ***p<0.001, n=5, Repeated-
measures ANOVA with post hoc Bonferroni test. (B) On d 21, lungs were excised and 
imaged separately. Results are reported as mean  SEM, Statistical analysis indicates 
Untreated Vs Ad5-TRAIL +528NP groups, *p<0.05, **p<0.01, n=5, one-way ANOVA. 
 
Discussion  
Immune-based therapies for solid tumors have the potential to improve long-term 
survival against cancers of various stages, including metastatic cancers 14,71,109,110. The goal 
of cancer immunotherapy is to activate T cells to recognize and eliminate tumor cells in an 
antigen -specific manner, which can be achieved by activation of APCs, mainly DCs and 
macrophages 111. TLR agonists stimulate DCs, resulting in increased expression of co-
stimulatory molecules and pro-inflammatory cytokine secretion, which in turn leads to T 
cell expansion 26,37. Unlike other TLRs present on the cell membrane, TLR 3, 7, 8 and 9 
are located on the luminal side of the endo/lysosome 86. Therefore, localization of the 
agonist molecule to endo/lysosomes is critical for triggering TLR 7/8 signaling and DC 
activation. In our study, 522NPs are efficiently internalized by APCs, which is consistent 
with previous reports that sub-micron size particles are suitable for DC uptake 58,80. 
Intracellular trafficking study showed 522NPs are located in endo/lysosomes after 
  57 
internalization, suggesting 522NPs can deliver 522 to the target intracellular compartment 
in DCs. 
While both Free522 and 522NPs significantly increased the overall co-stimulatory 
molecule expression in BMDCs, 522NPs resulted in higher CD86 expression than Free522. 
CD86:CD28 engagement results in stronger DC:T-cell interactions than CD80 
engagement, thereby initiating a more potent T cell response 112. BMDCs treated with 
522NPs also showed remarkable antigen (OVA)-presentation compared to those treated 
with Free522. One possible explanation for this finding is that positively charged OVA 
aggregated on the negatively charged 522NP surface and was internalized into DCs more 
efficiently to be processed by proteasome, as aggregation of proteins on nanoparticles 
increase uptake by APCs 76,113,114. Furthermore, a previous study suggested MyD88-
dependent TLR signaling can augment antigen cross-presentation by inducing phagosomal 
MHC I delivery from endosomes 115. In our case, this could have been achieved by 
persistent TLR 7 and 8 signaling enabled by sustained release of 522 from 522NPs. These 
results are consistent with other studies demonstrating improved immune response with 
nanoparticles over the soluble form of TLR ligand 67,116,117. 
An additional advantage of using nanoparticles as vaccine adjuvants is their tendency 
to accumulate in draining lymph nodes following S.C. or I.M. administration 65. Recent 
studies report nanoparticle drainage to the lymph node is dependent on the size of the 
particles 57,118. Small particles (20-200 nm) efficiently migrate directly into the lymphatic 
system while larger particles (>500 nm) are carried by DCs. In our studies, 522NPs were 
detected in the inguinal lymph nodes 1 h after S.C. injection. This relatively rapid 
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distribution is likely the result of their small size that allows direct drainage to the lymph 
node as well as DC-associated migration, which is supported by co-localization of 522NPs 
and CD11c+ cells in inguinal lymph node. 
OVA+522NP immunization dramatically increased the number of CD11c+ MHC II+ 
DCs in the draining lymph nodes relative to those in untreated and OVA alone group, 
suggesting 522NPs facilitate increased DC migration to the lymph nodes. Furthermore, co-
stimulatory molecule expression on these DCs was also higher following the immunization 
with OVA+522NPs. These data are consistent with the above studies showing nanoparticle 
encapsulated TLR7/8 agonist can potentiate DC migration and activation in draining lymph 
nodes by co-delivering antigens and persistent TLR 7/8 activation 76,113. 
CD8 T cells selectively recognize and eliminate target cells in an MHC I-restricted 
manner. Therefore, priming antigen-specific CD8 T cells is critical for achieving selective 
killing of target cells. We observed a 4.5-fold increase in the number of splenic OVA-
specific CD44hi CD8 T cells and a 2.5-fold increase in the number of OVA-specific IFN-
γ+ CD8 T cells when mice were immunized with OVA+522NP compared to untreated 
mice. Expression of CD44 implies these CD8 T cells can become memory T cells and 
respond to a secondary antigen encounter, which can provide protective immunity against 
cancer recurrence 119. IFN-γ plays a key role in cancer immunotherapy as it can enhance 
the survival and activation of DCs and T cells and increase the susceptibility tumors to T 
cells 92. Thus, the expansion of antigen-specific CD44hi and IFN-γ+ CD8 T cells strongly 
suggests 522NP immunization can prime antigen-specific effector CD8 T cells. 
Additionally, OVA+522NP immunized mice showed dramatically higher specific lysis 
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efficacy against OVA257-264-pulsed target cells compared to unpulsed control cells, further 
suggesting the combination of antigen and 522NP is highly effective in priming antigen-
specific CD8 T cells. 
To examine the extent to which this antigen-specific CD8 T cell response was 
effective against tumor cells, protective T cell immunity was investigated in primary and 
lung metastatic models induced by B16F10-OVA melanoma cells. Mice immunized with 
a combination of OVA and 522NP showed reduced lung tumor foci and significantly 
delayed tumor growth in these aggressive tumor models, demonstrating antigen+522NP 
immunization can potentiate protective immunity in an antigen-specific manner. 
Furthermore, OVA+522NP immunization was effective against established B16F10-OVA 
tumor model, where the overall immune response can be hampered by tumor evasion and 
immune-editing 120,121. These data demonstrate OVA+522NP immunization can elicit a T 
cell response even in immune-suppressive environments. Endogenous antigens often 
induce self-tolerance, which inhibits expansion of effector T cells 25. In our study, TRP-
2+522NP immunization was also effective in inhibiting the growth of established B16F10 
tumors. Although tumor inhibition was moderate when compared with OVA-based 
vaccine, this is expected given the relatively low expression of the TRP-2 epitope 
(compared to the antigenic epitopes within OVA) and its low binding affinity to Kb 97. 
Clinical trials with tumor vaccines using synthetic peptides derived from tumor 
antigens have met with limited success 98,99, with one limitation being MHC restriction, 
diminishing its utility in diverse populations 122. The sub-optimal efficacy could also result 
from poor immunogenicity of tumor antigens, tumor heterogeneity, emergence of tumor 
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cells that lose the targeted antigen, and immunological changes that decrease the initiation 
of a productive antitumor immune response 3,123. Autologous whole tumor cells contain all 
the antigens that a patient’s own immune system could potentially react with, representing 
a more exhaustive repertoire of tumor antigens 100. Therefore, we tested the adjuvant 
capacity of 522NPs with tumor cell lysate, a poorly immunogenic antigen source without 
immune stimulants 100,124. T cell responses were examined after immunizing the mice with 
MB49 cell lysates in which no tumor specific antigens have been identified to this point 
125. Although there were limitations to measuring MB49 tumor cell-specificity of T cells, 
our data demonstrate an increase in ‘Ag-experienced’ (CD11ahiCD8lo) CD8+ T cells when 
mice were immunized with 522NPs. Furthermore, cell lysate+522NP immunization was 
effective in delaying tumor growth in both prophylactic and therapeutic settings, 
suggesting 522NP can potentiate tumor-specific CD8 T cell response even with an 
undefined, poorly immunogenic antigen source. The therapeutic efficacy of Ad5mTRAIL-
mediated in situ vaccine against the metastatic RCC model further demonstrates the 
potency and versatility of these novel TLR 7/8 agonist loaded nanoparticles. We have 
previously reported both plasmacytoid and CD8α DCs are required for successful TRAIL-
based immunotherapy, which suggests 528NPs can efficiently activate both DC subsets 45. 
Additionally, the RCC study suggests nanoparticle-based vaccination is not limited to S.C. 
or I.M. routes but can also be utilized for intratumoral (I.T.) administration, where local 
delivery can enhance the immunogenicity of the vaccine 126,127. 
We have focused our efforts to investigate the ability of 522NPs to elicit an 
anticancer T cell response. Recent studies show TLR 7/8 agonists can also augment 
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antibody-dependent cell cytotoxicity (ADCC) of therapeutic antibodies by activating NK 
cells 128,129. Combination of TLR7 agonist and chemotherapy induces synergistic 
tumoricidal effects in breast cancer and vulval intraepithelial neoplasia 130,131. Radiation-
induced in situ vaccine using TLR7 agonist generates anti-tumor effects against lymphoma 
and melanoma 132,133. Combination of TLR7 agonist with PD-1 blockade suppressed tumor 
growth and prevented metastasis in head and neck squamous cell carcinoma (HNSCC) 
models 134. These reports strongly suggest TLR7/8 agonists can be used as versatile 
immune adjuvants in a variety of cancer immunotherapy settings. Furthermore, the well-
established use of biocompatible PLGA polymer for human applications and the recent 
approval of polymeric nanoparticles 135,136 suggests 522NP-based vaccines have the 
potential to achieve regulatory approvals.  
In this study, PLGA nanoparticles were utilized as the carrier for TLR 7/8 agonist 
with because of the biocompatibility of the polymer 137and the facile fabrication techniques 
that result in nanoparticle physiochemical properties for optimal DC internalization and 
LN drainage 51,56. Other studies have utilized PLGA nano and microparticles as anticancer 
vaccine adjuvants 67,77,138. Nanoparticle carriers including N-(2-
hydroxypropyl)methacrylamide (HPMA), chitosan and liposomes which have been 
utilized for vaccine delivery are also promising candidates for TLR 7/8 delivery carrier 
76,139,140. 
For successful clinical translation of 522NPs, further studies on safety of 522NPs 
and optimization of the vaccine formulation are required. Currently, the TLR7-specific 
agonist imiquimod is approved only for topical use. Therefore, potential adverse effects of 
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our novel TLR7/8-specific agonists including possible systemic cytokine and autoimmune 
reactions following S.C or I.M. delivery 126,141 need to be investigated. We also need to 
optimize the fabrication of 522NPs. The loading efficiency of 522 in the PLGA matrix was 
relatively low, which was similar to that reported in previous studies investigating the 
loading of imidazoqunolines in PLGA nanoparticles 142,143. Higher loading of 522 in 
nanoparticles could allow for fewer doses of the vaccine. With these issues addressed, we 
expect 522NPs can be a highly valuable and potent adjuvant for cancer immunotherapy. 
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3.1 Summary 
Synthetic imidazoquinoline-based toll-like receptor (TLR) 7/8 bi-specific agonists 
are promising vaccine adjuvants that can induce maturation and activation of dendritic cells 
(DCs) and activate them to secrete pro-inflammatory cytokines. However, in vivo efficacy 
of these small molecule agonists is often hampered by their fast clearance from the 
injection site, limiting their use to topical treatments. In this study, we investigated the use 
of acidic pH-responsive poly(lactide-co-glycolide) (PLGA) nanoparticles for endo-
lysosome specific release of 522, a novel TLR7/8 agonist. Bicarbonate salt was 
incorporated in the new formulation to generate carbon dioxide (CO2) gas in acidic pH, 
which can disrupt the polymer shell to rapidly release the payload. Compared to 
conventional PLGA nanoparticles, the pH responsive formulation resulted in 33-fold 
higher loading of 522. The new formulation demonstrated acid-responsive CO2 gas 
generation and drug release. The acid-responsive formulation increased the in vitro 
expression of co-stimulatory molecules on DCs and improved antigen-presentation via 
MHC I, both of which are essential for CD8 T cell priming. In vivo studies showed that 
pH-responsive formulation elicited stronger antigen-specific CD8 T cell and natural killer 
(NK) cell responses than conventional PLGA nanoparticles, resulting in enhanced 
anticancer efficacy in a murine melanoma tumor model. Our results suggest that acidic-pH 
responsive, gas-generating nanoparticles is an efficient TLR7/8 agonist delivery platform 
for cancer immunotherapy. 
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3.2. Introduction 
 Imidazoquinoline-based synthetic toll-like receptor (TLR) 7/8 agonists are 
promising vaccine adjuvants for cancer immunotherapy 144. TLR7/8 ligation triggers 
MyD88-dependent signaling in dendritic cells (DC), resulting in the production of pro-
inflammatory cytokines and co-stimulatory molecule expression 145. DC activation leads 
to expansion of activated natural killer (NK) cells and antigen (Ag)-specific CD8 T cells, 
both of which can kill malignant tumor cells 146. Current vaccine designs seek to deliver 
TLR agonists to DCs present in the skin and/or draining lymph nodes 57. However, small 
molecules are not retained in the skin for an extended duration because of rapid clearance 
from the well-vascularized dermal layers. This can result in undesirable systemic immune 
response 76. Further, following uptake by DCs, the agonist molecules have to distribute into 
endo-lysosomes to activate TLR 7/8 147. Thus, endo-lysosomal specific delivery of the 
agonists to DCs present in the dermal layers and lymph nodes can result in efficient TLR7/8 
ligation and superior anticancer immune response. 
We previously reported the use of poly(D,L-lactide-co-glycolide) (PLGA) 
nanoparticles for the delivery of a novel TLR7/8 agonist (termed ‘522’) 70. These 
nanoparticles (referred to as ‘522NP’) traffic to draining lymph nodes after subcutaneous 
(S.C.) injection and potently activate DCs. When combined with a peptide or whole tumor 
cell lysate-based Ag, 522NP immunization significantly increased the number of Ag-
specific effector CD8 T cells. Moreover, this vaccination modality enhanced the 
prophylactic and therapeutic anticancer efficacy in murine tumor models. Yet, these 
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nanoparticles were limited by low encapsulation efficiency (which limited the dose of 522 
that could be used) and non-specific agonist release. 
In this study, we investigated the use of acidic pH responsive PLGA nanoparticles 
to both increase agonist encapsulation and improve endo-lysosome (pH 4-6)-specific 
agonist release.  We hypothesized the higher dose and acidic-pH responsive release of 522 
would result in stronger activation of DCs and elicit robust CD8 T cell response for 
enhanced cancer immunotherapy. We adapted the use of bicarbonate salt, which generates 
carbon dioxide (CO2) gas in acidic pH, to incorporate pH responsiveness. Thus, NPs 
encapsulating both 522 and sodium bicarbonate were expected to generate CO2 gas in the 
acidic pH of the endo-lysosomes and mechanically disrupt the polymer matrix, resulting in 
a burst release of the encapsulated 522 in endo/lysosomes. In our study, co-incorporation 
of sodium bicarbonate resulted in significantly increased encapsulation of 522 and acidic 
pH responsive 522 release. Our data further suggest this new formulation elicits a much 
stronger anti-cancer immune response than conventional PLGA NPs.  
 
3.3. Materials and Methods 
3.3.1. Materials 
 Poly(lactide-co-glycolide) (PLGA) (50:50 lactide-glycolide ratio; 0.55-0.75 dl/g 
inherent viscosity) was purchased from Lactel (Birmingham, AL). TLR 7/8 agonist (termed 
‘522’) was synthesized and characterized as previously reported 42,75. Albumin from 
chicken egg white (ovalbumin, OVA), polyvinyl alcohol (PVA), 6-coumarin, ammonium 
acetate and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St Louis, 
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MO). Sodium bicarbonate, chloroform, acetonitrile, fluorescein conjugated ovalbumin, 
Foxp3 transcription factor staining buffer kit were purchased from Fisher Scientific 
(Rockford, IL). Fluorophore-labeled monoclonal antibodies for flow cytometry were 
purchased from Biolegend (San Diego, CA) (CD3, CD8, CD11c, CD80, CD49b, CD69, 
IFN-γ), eBioscience (San Diego, CA) (CD4, CD44, CD40, CD86) and Tonbo Biosciences 
(San Diego, CA) [I-A/I-E(MHC II)].  
 
Animals and cell line 
 All animal experiment protocols were reviewed and approved by Institutional 
Animal Care and Use Committee (IACUC) of the University of Minnesota. 
Immunocompetent C57BL/6 mice (7-8 weeks, female) were purchased from Charles River 
(Wilmington, MA) and housed under specific pathogen free (SPF) units in Research 
Animal Resources at the University of Minnesota.  
B16F10-OVA, a murine melanoma cell line which expresses ovalbumin, was 
provided by Dr. Brandon Burbach (University of Minnesota). B16F10-OVA was cultured 
in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 μg/mL 
streptomycin, 100 U/mL penicillin (hereafter referred to as complete RPMI) and 5 μg/mL 
G-418 Disulfate (Research products international, Mt Prospect, IL).  
 
3.3.2. Methods 
Fabrication of nanoparticles 
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 522NP formulation was prepared as previously reported 70, using 3 mg 522 and 44 
mg PLGA. Acidic pH-responsive nanoparticle formulation of 522 (hereafter referred to as 
‘522GGNP’) were formulated using a variation of the water-in-oil-in-water (w/o/w) 
double-emulsion solvent evaporation technique. For the primary w/o emulsion, the 
aqueous phase was prepared by dissolving 2.5 mg of sodium bicarbonate in 500 μl of 1% 
w/v PVA in endotoxin-free distilled water (D.I. water). This aqueous phase was transferred 
to the oil phase, which consisted of 44 mg PLGA and 3 mg 522 dissolved in 2 ml 
chloroform. This mixture was sonicated using probe sonicator (Sonicator XL, Misonix, 
Melville, NY) for 1 min to form w/o emulsion. This primary emulsion was then added to 
8 ml of 2% PVA and sonicated for 5 min to form secondary w/o/w emulsion. The final 
emulsion was stirred for ~18 h, followed by 1 h in a desiccator under vacuum to evaporate 
chloroform. Nanoparticle dispersion formed was washed by centrifugation (Optima XPN-
80 Ultracentrifuge, Beckman Coulter Inc., Fullerton, CA) (35,000 RPM, 35 min) and 
reconstitution with D.I. water three times. After final wash, nanoparticles were resuspended 
in D.I. water and lyophilized (Labconco FreeZone 4.5, Kansas City, MO). Nanoparticles 
were stored at -20°C until use. 
 
Characterization of nanoparticles 
 To determine size and zeta potential of the nanoparticles, ~1 mg of nanoparticles 
were dispersed in D.I. water and sonicated for 30 sec and subjected to dynamic light 
scattering (DLS) analysis (DelsaTM Nano C, Beckman Coulter Inc.). Nanoparticles were 
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also imaged using a cryo-transmission electron microscope (TEM) (FEI Tecnai G2 F30) 
as described previously 148. 
 The amount of 522 encapsulated into the nanoparticles was quantified using high-
performance liquid chromatography (HPLC; Beckman Coulter) as previously reported 70. 
The amount of sodium bicarbonate encapsulated into the nanoparticles was measured by 
quantifying sodium ion using inductively coupled plasma optical emission spectrometry 
(ICP-OES) (Thermo Scientific iCAP 6000 Series). Briefly, a mixture of nitric acid and 
hydrochloric acid (3:1 molar ratio) was added to 1 mg of nanoparticles in a glass vial. Glass 
vial was heated to 90°C in an oil bath for 5 h to fully dissolve nanoparticles. Mixture was 
then cooled and diluted with D.I. water for ICP-EOS analysis. 
 
Cytotoxicity of nanoparticles 
 Splenocytes from C57BL/6 mice were used to measure cytotoxicity of 
nanoparticles. A single cell suspension of splenocytes was prepared using an established 
protocol 45. Briefly, spleens were mechanically homogenized using gentleMACS 
Dissociator (Miltenyi BioTeck Inc., Auburn, CA). The cell suspension was washed with 
HBSS and digested in HBSS supplemented with 0.15 mg/ml DNAse I (Sigma) and 0.56 
Wuensch units/ml Liberase Blendzyme 3 (Roche, Branford, CT). After 30 min, red blood 
cells (RBCs) were removed by incubating the cell suspension with lysis buffer (Pharm 
Lyse, BD Bioscience, San Jose, CA) with for 5 min. Cells were then washed with PBS and 
suspended in HBSS until further use. To evaluate cytotoxicity of nanoparticles, mouse 
splenocytes (2 x 104 cells/well) were incubated with 522GGNP (15.6~250 μg/ml) in a 96-
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well plate. After 48 h incubation period, supernatants were collected and cytotoxicity was 
determined according to the manufacturer’s protocol (LDH Cytotoxicity Assay Kit, 
Thermo). 
 
TLR7 and 8 reporter cell assay 
Human TLR-specific reporter cell assays were performed as previously reported 75. 
Reporter cells (HEK-BlueTM-hTLR7 and 8, InvivoGen, San Diego, CA) (40,000 cells per 
well) were seeded in 96-well cell culture plate, and soluble form of 522 in DMSO (referred 
to as ‘Free522’) (30 µM) or 522GGNP (522 equivalent to 30 µM) were added to the wells. 
After 24 h, supernatants were collected for measuring TLR-specific activity according to 
manufacturer’s protocol. 
 
In vitro release kinetics 
Release of 522 from 522GGNPs was determined in acidic (5.5, 6.5) and neutral pH 
(7.4) buffers. Release buffer was added to 1 mg of nanoparticles in 2 ml plastic tubes. 
Sample tubes were incubated in a water bath shaker at 37°C (100 RPM). At pre-determined 
time points, samples were centrifuged and 0.5 ml of the supernatant was collected. Sample 
tubes were refilled with fresh 0.5 ml buffer to maintain a constant volume. Collected 
samples were lyophilized and agonist was extracted with methanol. Amount of agonist 
released at each time point was analyzed using HPLC.   
Generation of CO2 bubbles was tested as previously described 
149. Briefly, 10 ml of 
buffer solution (pH 5.5 or 7.4) was added to ~6 mg of nanoparticles in a 15-ml plastic tube. 
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The CO2 bubbles generated were visualized using an ultrasound imaging system 
(Vevo2100, Visualsonics) equipped with a 21 MHz transducer. Intensity of bubbles were 
measured by quantifying white values in ultrasound images using ImageJ software. Sodium 
bicarbonate (50 mg) and 522NPs (6 mg) were used as positive and negative controls, 
respectively. 
 
Culture of bone marrow-derived dendritic cells (BMDCs) 
BMDCs were prepared as described previously 70. Briefly, bone marrow precursor 
cells were collected from tibias and femurs from C57BL/6 mice. Cells were filtered with a 
70 micron nylon mesh and red blood cells were removed using lysis buffer to obtain single 
cell suspension. Cells were seeded in petri dish and incubated with complete RPMI media, 
supplemented with 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-
CSF) (PeproTech, Rocky Hill, NJ), 10 ng/mL IL-4  and 50 μM 2-mercaptoethanol (Sigma) 
for 6 d to generate immature BMDCs. 
 
Uptake of nanoparticles in BMDCs 
To label and track nanoparticles, 6-coumarin, a hydrophobic fluorescent dye, was 
co-encapsulated in 522GGNPs by adding 300 µg of 6-coumarin to the organic phase during 
522GGNP fabrication 150. For in vitro cell uptake study, BMDCs were seeded in a 24-well 
culture plate (106/well), and then incubated with NPs (0.2 mg/ml) for 2 h.  Cells were 
collected, washed with PBS, and stained with anti-CD11c mAb. Uptake of NPs by BMDCs 
was examined by monitoring 6-coumarin-associated fluorescence intensity by flow 
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cytometry (BD LSR II). Flow cytometry data were analyzed using FlowJo software 
(TreeStar Inc., Ashland, OR). 
Intracellular distribution of NPs was imaged by confocal laser scanning microscopy 
(Olympus FluoView FV1000 BX2 Upright Confocal). Glass-bottomed petri dishes (35 
mm, MatTek) were coated with poly-L-lysine solution (Sigma) for 30 min. After 30 min, 
the poly-L-lysine solution was removed and petri dishes were rinsed with D.I. water twice. 
Dishes were dried in a laminar flow hood for 2 h, and BMDCs (3x105/dish) were added. 
After 24 h, BMDCs were incubated with NPs (0.2 mg/ml) for 4 h, and rinsed with PBS. 
Cells were counterstained with LysoTracker® Red DND-99 (Thermo Scientific) and 
imaged without fixation. 
 
In vitro BMDC activation 
BMDCs (106/well) were added to a 24-well cell culture plate. Following 
attachment, BMDCs were treated with OVA (20 µg) alone or OVA combined with 522NPs 
(100 µg/ml, equivalent to 120 ng/ml of 522) or 522GGNPs (100 µg /ml, equivalent to 4 
µg/ml of 522) for 24 h. Expression of co-stimulatory molecules (CD40, CD80 and CD86) 
and MHC II on BMDCs was measured by flow cytometry. 
 
In vitro BMDC antigen uptake and presentation 
Antigen uptake by BMDCs was measured by flow cytometry. A solution of 
fluorescein conjugated OVA (OVA-FITC, Thermo) in PBS (10 µg/ml) was added to 
BMDCs (1x106/well). Subsequently, cells were incubated with 0.1 mg of 522NP or 
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522GGNP for 6 h. Cells were then washed with PBS and stained with anti-CD11c mAb. 
FITC associated fluorescence intensity was measured in CD11c+ cells by flow cytometry. 
To examine antigen presentation by BMDCs, the above experiment was repeated by 
incubating unlabeled OVA (20 µg) with BMDCs for 24 h. After 24 h, BMDCs were 
harvested and stained with anti-CD11c antibody and anti-OVA257-264 (SIINFEKL) peptide 
bound to H-2Kb (clone 25-D1.16; eBioscience) antibody and analyzed by flow cytometry. 
 
Immunization protocol 
 Vaccine doses were prepared by combining OVA (100 µg) with 1.5 mg of 522NPs 
(equivalent to 1.8 µg of 522) or 522GGNPs (equivalent to 60 µg of 522) in 200 µl of sterile 
PBS. Each dose was injected s.c. to the left and right thighs (100 µl each).  Mice were 
dosed once every day for five consecutive days. 
 
In vivo T cell and NK cell activation assays 
Immunocompetent C57BL/6 mice were immunized daily as described above for 5 
d (d 1~5). On d 10, mice received 100 µg of OVA257-264 peptide via tail vein injection and 
euthanized after 4 h. Spleen was collected and a single cell suspension of splenocytes was 
prepared as described above and stained with anti-CD3, anti-CD4, anti-CD8, anti-CD44, 
anti-CD49b and anti- IFN-γ antibodies as well as with OVA257-264:H-2Kb Tetramer-APC. 
Intracellular staining of IFN-γ was conducted according to the manufacturer’s protocol 
(Foxp3/Transcription Factor Staining Buffer Set, eBioscience). Number of cells per spleen 
was calculated by using counting beads (eBioscience) in flow cytometry analysis.  
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Tumor challenge 
B16F10-OVA cells (5 x 105) were suspended in 100 µl PBS and inoculated s.c. in 
the abdominal region near the right thigh of C57BL/6 mice. Tumor volume was measured 
as previously described 70. Once the tumor volume reached 100 mm3, mice were 
immunized as described above. Mice that grew tumors >1500 mm3 and/or developed 
ulcerations in the tumor were euthanized.   
 
Statistical analyses 
Results were shown as either mean ± standard deviation (SD) or mean ± standard 
error of the mean (SEM). One-way analysis of variance (ANOVA) with post hoc Tukey 
test was used to determine the statistical significance of the observed differences between 
the treatment groups, unless otherwise noted. A p-value <0.05 was considered statistically 
significant; p-values were indicated using the following scheme: *p<0.05, **p<0.01, 
***p<0.001, n.s = not significant (p>0.05). Data was analyzed using GraphPad Prism 7 
software.  
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3.4. Results 
3.4.1. Physicochemical characterization and TLR 7/8 specific activity by NPs 
 522GGNPs were similar to 522NPs in physicochemical characteristics. 522GGNPs 
appeared as discrete spheres and without apparent aggregation when imaged by cryo-TEM 
(Figure 3.1A). Average diameter of 522GGNP measured by DLS was 202 ± 3 nm, which 
was similar to that of 522NPs (210 ± 2 nm) (Table 3.1). 522GGNPs were negatively 
charged, with an average zeta-potential of -16.5 ± 2 mV, which was comparable to that of 
522NPs (-22.6 ± 1.9 mV). However, 522 encapsulation was 33-fold higher in 522GGNPs 
(40 µg/mg of NP) than in 522NP (1.2 µg/mg of NP). Loading of sodium bicarbonate in 
522GGNP was confirmed using ICP-EOS and was 8.8 µg/mg of NP. 
  522GGNPs caused  negligible cytotoxicity against mouse splenocytes (Figure 
3.1B), which is consistent to the previous studies reporting minimal cytotoxicity of PLGA 
nanoparticles 151,152. We then investigated whether 522GGNPs can specifically activate 
TLR7 and TLR8 in TLR reporter cells. As shown at Figure 3.1C, 522 maintained its TLR7 
and 8 activity after encapsulation in NPs.  
 
(A)                                                                                        (B) 
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(C) 
 
Figure 3.1.  522GGNP in vitro efficacy 
(A) A representative cryo-TEM image of 522GGNPs. Scale bar, 100 nm. (B) Cytotoxicity 
of 522GGNP against mouse splenocytes. Treatments were incubated with mouse 
splenocytes for 48 h and cytotoxicity was measured by LDH assay. Results are reported as 
mean  SD, n=4. (C) Human TLR7 or TLR8 specific reporter cells were incubated with 
DMEM, Free522 and 522GGNP for 24 h. TLR specific activation by treatments was 
measured by SEAP activity at OD650. Results are reported as mean  SD, n=4, ***p<0.001, 
One-way ANOVA. 
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Table 3.1. Physiochemical characterization of 522NPs and 522GGNPs 
Particle size, zeta-potential and polydispersity index of NPs were measured by DLS. 
Amount of 522 loaded in nanoparticles was quantified using HPLC. Amount of sodium 
bicarbonate in the 522GGNPs was measured using ICP-EOS. Results are reported as mean 
 SD, n=3. 
 
 
Table 3.2. Physiochemical characterization of control 522 NPs 
Particle size, zeta-potential and polydispersity index of NPs were measured by DLS. 
Amount of 522 loaded in nanoparticles was quantified using HPLC. Results are reported 
as mean  SD, n=3. 
 
3.4.2. In vitro release kinetics and gas-generation by NPs 
522GGNPs showed acidic pH-responsive release kinetics (Figure 3.2A). In the 
first hour, 522GGNPs released ~90% and ~72% of encapsulated 522 in pH 5.5 and 6.5 
buffers. In the neutral pH, however, 522GGNPs released only ~23% of the encapsulated 
522 in the first 1 h, followed by slower release (~85%) over the next 48 h. We then 
monitored CO2 generation by 522GGNPs using ultrasound imaging (Figure 3.2B). In pH 
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5.5, sodium bicarbonate (positive control) generated large number of CO2 bubbles. 
Generation of CO2 bubbles was significantly lower but still detectable in pH 7.4. For 
522NP, CO2 generation was negligible at both pH’s. 522GGNPs demonstrated significant 
CO2 generation in acidic pH but not in pH 7.4 (Figure 3.2C). These results provide direct 
evidence that 522GGNP generate CO2 bubbles in acidic pH. 
(A) 
 
(B)
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(C) 
 
Figure 3.2.  522GGNP in vitro release kinetics and gas generation profiles 
(A) Cumulative release of 522 from 522GGNP was measured in pH 5.5, 6.5 and 7.4. 
Results are reported as mean  SD, n=3. (B) Gas generation from sodium bicarbonate and 
nanoparticles was visualized by ultrasound imaging. Representative ultrasound images at 
pH 5.5 and 7.4 are shown. (C)  Generated gas was quantified by measuring histogram 
intensity of white signals. Results are reported as mean  SD, n=4. ***p<0.001, One-way 
ANOVA. 
 
3.4.3. NP uptake by BMDCs  
 Uptake of 522GGNPs by DCs and their trafficking to the endo/lysosomal 
compartment is critical for efficient TLR7/8 activation 153. As shown in Figure 3.3A, there 
was a clear shift in fluorescence intensity of BMDCs treated with NPs, which indicates that 
BMDCs were associated with the labeled NPs. To further investigate the internalization 
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and intracellular trafficking, we imaged BMDCs using confocal laser microscopy. NPs 
(green fluorescence) were located in both the cytosol and endo/lysosomes (stained with red 
fluorescence) (Figure 3.3B). The presence of merged signal (yellow fluorescence) 
confirmed that a fraction of internalized NPs colocalized with endo/lysosomes. 
 
(A) 
 
(B) 
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Figure 3.3.  NP uptake by BMDC  
(A) 6-coumarin labeled 522GGNPs were incubated with BMDCs (CD11c+) for 2 h, and 
change in fluorescence intensity of BMDCs was measured by flow cytometry. 
Representative histograms of fluorescence intensity are shown. (B) A representative 
confocal image of BMDCs after incubation with 522GGNPs is shown. Green: 
nanoparticles, red: endo/lysosomes, yellow: merged signal of nanoparticle and 
endo/lysosomes. Scale bar, 20 µm.  
 
3.4.4. BMDC activation 
 To elicit CD8 T cell response, DC expression of co-stimulatory molecules CD40, 
CD80 and CD86 is essential 154. Therefore, we measured the extent of DC activation in the 
presence of 522GGNPs by measuring co-stimulatory molecule expression. OVA was used 
as a model antigen in these studies. As expected, OVA alone had negligible effect on DC 
activation. CD40 expression increased from 5% for untreated to 89% for OVA+522GGNP 
treatment, while 11% and 69% of the BMDC expressed CD40 when treated with OVA 
only and OVA+522NP, respectively (Figure 3.4). OVA+522GGNP treatment also 
increased the frequency of BMDC expressing CD86 to 71%, while OVA only and 
OVA+522NP treatment resulted in 18% and 33% of the BMDC expressing CD86, 
respectively. CD80 also showed similar trend, where OVA+522GGNP treatment induced 
66% of the cells to expression CD80, while OVA only and OVA+522NP treatments 
resulted in 16% and 23%, respectively. In addition to co-stimulatory molecule 
upregulation, OVA+522GGNP increased MHC II expression on DCs by 54%, while OVA 
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only and OVA+522NP treated DCs had 29% and 34% expression, respectively.  These 
data show 522GGNPs results in enhanced DC activation compared to 522NPs. 
 
 
Figure 3.4.  BMDC activation 
Flow cytometry analysis of CD40, CD80, CD86 and MHC II expression on BMDCs after 
48 h incubation with treatments. Results are reported as mean  SD, n=4, ***p<0.001, 
One-way ANOVA. 
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3.4.5. Antigen uptake and presentation 
We also investigated the other key feature of successful DC activation: Ag uptake 
and presentation via MHC I 155. We determined the effect of co-incubation with 522GGNPs 
on Ag uptake by DCs using fluorescently-labeled OVA. After 1 h incubation, a significant 
increase in DC fluorescence intensity was observed (Figure 3.5A,B), suggesting 
internalization of OVA-FITC. There was a statistically significant increase in OVA uptake 
when DCs were co-treated with 522NP, and the highest increase was detected when DCs 
were co-treated with 522GGNPs. Uptake of Ag does not necessarily leads to Ag 
presentation by DCs 156. Therefore, we measured OVA257-264 (SIINFEKL) peptide:MHC I 
complex on DCs, 157. Compared to Ag uptake, OVA+522GGNP treated BMDCs showed 
4- and 2-fold higher expression of OVA257-264 (SIINFEKL) peptide:MHC I complex 
compared to the OVA only and OVA+522NP incubated BMDCs, respectively (Figure 
3.5C). 
 
 
(A)                                                                                                    
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(B)                                                                                     (C) 
  
 
Figure 3.5. Antigen uptake and presentation via MHC I 
(A,B) FITC labeled ovalbumin (OVA-FITC) and treatments were incubated with BMDCs 
for 6 h. (A) A representative histogram showing fluorescence intensity of BMDCs is 
shown. (B) FITC fluorescence was quantified as geometric mean fluorescence intensity. 
Results are reported as mean  SD, n=4, *p<0.05, ***p<0.001, One-way ANOVA. (C) 
BMDCs were incubated with OVA and/or NPs for 48 h.  BMDCs expressing OVA257-264 
(SIINFEKL) peptide bound to H-2Kb (MHC I) were analyzed by flow cytometry.  Results 
are reported as mean  SD, n=3, **p<0.01, One-way ANOVA. 
 
 
3.4.6. In vivo T cell assay 
We next examined the extent of T cell response after immunizing 
immunocompetent mice. We first measured CD4 T cells, which enhance CD8 T cell 
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activation by secreting IFN-ɣ 158,159. The number of IFN-ɣ+ CD4 T cells increased 2-fold 
when mice were immunized with OVA+522GGNP compared to untreated and OVA only 
groups (Figure 3.6A). OVA+522NP treated mice also showed increased IFN-ɣ+ CD4 T 
cells compared to the two control groups but was less effective than OVA+522GGNP. To 
determine the activation of Ag-specific cytotoxic CD8 T lymphocytes that can eradicate 
tumor cells 160,161, we first quantitated the number of the OVA257-264-specific CD44
high CD8 
T cells 162 to determine expansion. OVA+522GGNP immunization increased the number 
of CD44high CD8 T cells by 4- and 2.5- fold compared to untreated and OVA only-treated 
mice, respectively (Figure 3.6B). Moreover, OVA257-264-specific IFN-ɣ+ CD8 T cells also 
increased 3- and 2.5- fold when mice were immunized with OVA+522GGNP compared to 
untreated and OVA only group, respectively (Figure 3.6C). Consistent with our previous 
study 70, OVA+522NP immunization increased OVA257-264-specific CD8 T cell responses 
compared to controls; however, OVA+522GGNP immunization induced stronger T cell 
responses than OVA+522NP immunization. 
 
(A)                                                           
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(B)                                                                                           (C)  
  
 
Figure 3.6.  In vivo T cell activation 
Following immunization, spleens were collected and analyzed by flow cytometry. (A) 
Number of IFN-γ+ CD4 T (CD3-CD4+) cells; (B) Number of OVA257-264-specific CD44high 
CD8 T (CD3-CD8+) cells; (C) Number of OVA257-264-specific IFN-γ+ CD8 T cells. Results 
are reported as mean  SEM, **p<0.01, ***p<0.001, n=4, one-way ANOVA. 
 
3.4.7. In vivo NK cell assay 
CD70 is a co-stimulatory molecule expressed on DCs that interacts with CD27 on 
NK cells and induces NK cell activation 163. As seen in Figure 3.7A, both 522NPs and 
522GGNPs induced upregulation of CD70 on DCs. We then investigated NK cell 
activation in vivo. Frequency of both CD69high  and IFN-ɣ+ NK cells increased 2.5-fold 
compared the untreated group (Figure 3.7B,C). Consistent with the results of the T cell 
activation studies, 522NP immunization also induced NK cell activation, but the extent 
was less than that with 522GGNP immunization. 
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(A)                                                      
 
(B)                                                                           (C)  
 
Figure 3.7.  In vivo NK cell activation 
(A) Expression of CD70 on BMDCs was measured by flow cytometry. Results are reported 
as mean  SD, *p<0.05, ***p<0.001, n=3, one-way ANOVA. (B,C) Spleens of immunized 
mice were harvested and analyzed by flow cytometry. (B) Number of CD69high NK (CD3-
CD49b+) cells. (C) Number of IFN-γ+  NK cells. Results are reported as mean  SEM, 
*p<0.05, ***p<0.001, n=4, one-way ANOVA. 
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3.4.8. Tumor challenge 
In vivo therapeutic efficacy of OVA+522GGNP immunization was evaluated in a 
murine melanoma tumor model. B16F10-OVA tumors became palpable on d 11 after 
tumor cell injection and mice were immunized by once daily dosing of the vaccine 
formulation from d 11 to d 15. Both untreated and OVA alone treated groups showed rapid 
tumor growth, where all of the mice had tumors 1500 mm3 by d 22 and d 24, respectively 
(Figure 3.8). Consistent with our previous study 70, OVA+522NP immunization was 
effective in inhibiting tumor growth (p<0.001). However, OVA+522GGNP immunization 
showed enhanced therapeutic efficacy compared to OVA+522NP vaccination (p<0.001). 
Average tumor volume of OVA+522NP and OVA+522GGNP immunized animals on d 24 
was 729 mm3 and 339 mm3, respectively. 
 
 
Figure 3.8.  Tumor challenge using B16F10-OVA melanoma tumor model  
  89 
C57BL/6 mice with established B16F10-OVA tumors were randomized and vaccine doses 
were administered over five days (d 11-15). Results are reported as mean  SEM, 
***p<0.001, n=4~5, Two-way ANOVA with post hoc Tukey’s test. 
 
3.5. Discussion 
 
Nanoparticulate delivery of TLR7/8 agonists can broaden their application in 
cancer immunotherapy. Currently, TLR7/8 agonists are limited to topical administration 
(ClinicalTrials.gov;  NCT01808950, NCT01676831) and intratumoral injection 
(NCT02556463). In the studies where TLR7/8 agonists have been utilized as the vaccine 
adjuvant, peptides derived from tumor-associated Ag (TAA) were administered S.C. 
(NCT01748747, NCT00960752) and the TLR7/8 agonists were applied topically on the 
tumor. However, co-delivery of antigen and adjuvant to the same Ag-presenting cells is 
critical for eliciting Ag-specific T cell response 77. Therefore, a formulation that can deliver 
TLR7/8 agonists via S.C. or I.M. injection together with TAA-peptides is needed. 
We investigated PLGA NPs for TLR7/8 agonist delivery because of the excellent 
biocompatibility and safety profile of PLGA 151. Further, nanoparticles 200 nm are 
preferentially taken up by DCs, and can also directly drain to lymph nodes 57. However, 
low drug loading was an issue in our previous study (~1 µg/mg of NPs) 70. Low 
encapsulation of imidazoquinoline derivatives in PLGA nanoparticles has been reported 
previously 142,143. 522 is a moderately hydrophobic compound (logP = 2.74). However, it 
has increased solubility in 2.5 % PVA solution (30 µg/ml). Thus, 522 can diffuse out from 
the oil phase to aqueous phase during the fabrication process, which appears to lead to low 
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encapsulation efficacy. In the present study, encapsulation efficiency increased several fold 
in 522GGNP compared to our previous 522NP. We presume the increased encapsulation 
of 522 in 522GGNP occurred because of two reasons. First, the double-emulsion 
evaporation method can result in higher encapsulation efficiency for both hydrophilic and 
hydrophobic drugs 164. Second, the presence of the bicarbonate salt in the primary aqueous 
phase could also have affected the drug loading. The use of 1% PVA without sodium 
bicarbonate as the primary phase resulted in only 6% encapsulation efficacy. We also tested 
1% PVA solutions containing sodium chloride or sodium phosphate, as the addition of salt 
in primary emulsion can stabilize the emulsion 165. In our hands, these salt solutions failed 
to form a stable emulsion with 522 and resulted in 5% and 7% encapsulation efficiencies, 
respectively. In addition to their low encapsulation efficiency, these nanoparticles also had 
larger size. 
 The presence of sodium bicarbonate also contributed to the acidic pH-response 
release kinetics of 522GGNPs. Utilizing the bicarbonates to introduce pH-sensitive drug 
release has been previously reported 166,167. In acidic pH, bicarbonates react with H+ to form 
carbonic acid, which dissociates to release CO2 gas that can mechanically disrupt the 
polymer shell and facilitate the rapid release of the drug payload. Ultrasound imaging 
confirmed acidic pH-dependent gas-generation by 522GGNPs but not 522NPs, which 
supports the proposed mechanism of drug release. Acidic-pH responsive release can be 
important for effective DC activation by TLR7/8 agonists. Both TLR7 and 8 are located 
on the luminal side of endo-lysosomes, which are acidic cellular compartments (pH 4~6) 
153. From flow cytometry and confocal data, we confirmed 522GGNPs localized to 
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endo/lysosomes in DCs. Based on these results, we expect 522GGNPs can improve the 
delivery of 522 to the endo-lysosomes 147,166. Compared to the conventional 522NPs, 
522GGNPs resulted in a much stronger DC activation, further substantiating improved 522 
delivery to the target site. In addition to upregulation of co-stimulatory molecules, 
522GGNP significantly enhanced the antigen presentation via MHC I. 
T cells are key players in cancer immunotherapy because of their ability to directly 
kill the tumor cells and activate other immune cells 160,161. In this study, we found 
522GGNP immunization increased the number of IFN-ɣ+ CD4 T cells, which can activate 
CD8 T cells and NK cells 159,168. This data implies 522GGNP immunization can potentiate 
a Th1 response 169. As CD4 T cells are primarily activated via CD40-CD40L signaling 170, 
it is likely 522GGNPs’ ability to increase CD40 expression on DCs enables the expansion 
of effector CD4 T cells. In addition, increased expression of MHC II on 522GGNP treated 
DCs further suggests 522GGNP is effective in activating effector CD4 T cells 171. 
522GGNP immunization also increased the number of Ag-specific effector CD8 T cells. 
Consistent with our previous study 70, OVA+522NP increased both OVA257-264-specific 
CD44high CD8 T cells and OVA257-264-specific IFN-ɣ+ CD8 T cells compared to OVA only, 
which demonstrates the potent adjuvanticity of polymeric nanoparticles encapsulating 
TLR7/8 agonists. The greater OVA257-264-specific CD8 T cell expansion observed with 
522GGNP immunization compared to that with 522NP was likely the result of enhanced 
Ag-presentation and co-stimulatory molecule signaling by DCs that primed CD8 T cells 
and further potentiated by IFN-ɣ+ CD4 T cells. 
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NK cells also play major role in cancer immunotherapy IFN-ɣ secretion upon 
activation and directly kill the tumor cells with cytotoxic granules 172. As NK cells can be 
activated by DC-NK cell interaction and IFN-ɣ secreted by T cells 173, we investigated NK 
cell expansion following 522GGNP immunization. Similar to the observed increase in T 
cell activation, 522GGNP immunization increased both CD69high NK cells and IFN-ɣ+ NK 
cells. CD69 expression triggers cytolytic activation of NK cells 174. Activation of NK cells 
can provide several benefits in cancer immunotherapy. First, NK cells can kill the tumor 
cells before CD8 T cells are primed by DCs. It has been reported that 7-9 days are required 
to generate antigen-specific CD8 T cells after immunization, but the tumor cells continue 
to proliferate during that time span 175. However, NK cells become effective as early as 
few hours after immunization, and kill the tumor cells before CD8 T cells are primed 176. 
This leads to another benefit of activated NK cells, as NK cells can induce immunogenic 
tumor cell death 177,178. As a result, more TAAs will be available to DCs. In addition, IFN-
ɣ secretion by NK cells can modulate other Ag presenting cells and T cells for Th1 response 
179.  
To evaluate whether enhanced antigen-specific CD8 T cell and NK cell response 
by OVA+522GGNP immunization could lead to improved anticancer efficacy, we 
performed a tumor challenge study using B16F10-OVA tumor model. While OVA+522NP 
immunization was effective in inhibiting tumor growth compared to untreated and OVA 
only treatment, OVA+522GGNP immunization showed superior therapeutic efficacy. 
Interestingly, OVA+522GGNP showed effectiveness two days earlier (d 16) than 
OVA+522NP (d 18). As 7~10 days are required to prime CD8 T cells, it is possible that 
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activated NK cells could have contributed to the early effectiveness of OVA+522GGNP 
treatment. Taken together, our data thus demonstrate 522GGNP can elicit robust antigen-
specific CD8 T cell and NK cell responses, resulting in enhanced therapeutic efficacy 
compared to that with 522NP.  
In this study, we introduced the use of an acidic pH responsive NP formulation for 
endo/lysosomal delivery of TLR7/8 agonists. The new formulation was characterized by 
higher drug encapsulation and acidic-pH responsive release kinetics. 522GGNPs showed 
more potent NK cell and CD8 T cell responses than 522NPs. Our results suggest acidic-
pH responsive, gas-generating nanoparticles is an efficient drug delivery platform for 
TLR7/8 agonists for cancer immunotherapy. 
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Chapter 4. 
 
 
Combination of sunitinib and PD-L1 blockade 
enhances anticancer efficacy of  
TLR7/8 agonist-based nanovaccine 
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4.1. Summary 
 
Cancer vaccines composed of tumor-associated antigens (TAAs) and toll-like 
receptor (TLR) agonists have shown promising antitumor efficacy in pre-clinical studies 
by generating antigen-specific CD8 T cells, but translation of cancer vaccines to the clinic 
has been limited due to response variabilities and recurrence of tumor. The tumor 
microenvironment has various immune escape mechanisms that neutralize CD8 T cells, 
which can lead to these sub-optimal therapeutic efficacies. Therefore, we hypothesized that 
modulation of the tumor microenvironment can augment CD8 T cell activation and 
enhance therapeutic efficacy of cancer vaccine. To accomplish this enhancement, we aimed 
to eliminate immune suppressive cells and block their inhibitory signaling. Combination 
of the tyrosine kinase inhibitor (TKI) sunitinib with a nanoparticle-based cancer vaccine 
(nanovaccine) resulted in reduction of immune-suppressive myeloid-derived suppressive 
cells (MDSCs) and regulatory T cells (Tregs). Blockade of programmed death-ligand 1 
(PD-L1) using anti-PD-L1 antibody was adapted to reduce CD8 T cell exhaustion. 
Combination of nanovaccine+sunitinib+PD-L1 antibody treatment reduced PD-L1high M2 
macrophages and MDSCs and upregulated activation of CD8 T cells in the tumor. 
Nanovaccine+sunitinib+PD-L1 antibody treatment also stimulated antigen-specific CD8 T 
cell response, which lead to significant therapeutic efficacy in a murine tumor model. These 
results suggest that modulation of tumor microenvironment using sunitinib and PD-L1 
blockade can significantly enhance the anti-tumor efficacy of cancer nanovaccine. 
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4.2. Introduction 
Synthetic vaccine adjuvants have shown considerable potential in stimulating a 
robust cytotoxic CD8 T cell response, which is critical for eradicating established tumors 
33,180. In our previous studies, we described the development of a series of novel 
imidazoquinoline derivatives that activate Toll-like receptor (TLR) 7 and/or 8 and 
stimulate robust pro-inflammatory cytokine production 42. Encapsulation of these agonists 
in polymeric nanoparticles improved their ability to activate dendritic cells (DCs) and 
resulted in a robust expansion of antigen-specific CD4 and CD8 T cells and enhanced 
cytotoxic response 70. 
Nanoparticle-encapsulated agonist induced strong protective immunity in 
prophylactic tumor models; however, it was less effective against established tumors 70. 
Sub-optimal outcomes in the therapeutic models may have resulted from tumor-induced 
immune suppression 181. Tumor microenvironment is highly immune suppressive 182, as 
tumor growth leads to the recruitment of immunosuppressive cells including myeloid 
derived suppressive cells (MDSCs), regulatory T cells (Tregs) and M2 macrophages, which 
deactivate natural killer (NK) cells and T cells 183. Tumors also upregulate programmed 
death-ligand 1 (PD-L1), which ligates PD-1 on CD8 T cells and induces T cell exhaustion 
184. Therefore, modulating the immunosuppressive tumor microenvironment can 
significantly improve the effectiveness of anticancer vaccines. 
Previous pre-clinical and clinical studies show sunitinib, a tyrosine-kinase inhibitor 
(TKI) used in the treatment of renal cell carcinoma (RCC) 185, can reduce MDSC and Treg 
populations 186,187. Further, several tumors express high levels of PD-L1 when exposed to 
  97 
IFN-ɣ, such as that following vaccination 188,189. Additionally, immunosuppressive 
macrophages (M2) and MDSCs express high levels of PD-L1 190. PD-L1 blockade using 
anti-PD-L1 antibody can reduce the T cell exhaustion in the tumor and enhance the 
therapeutic efficacy of the nanovaccine. 
In this study, we examined the ability of sunitinib and anti-PD-L1 blockade enhance 
the anticancer efficacy of our TLR7/8 agonist-based nanovaccine. We determined the 
effect of sunitinib co-therapy on MDSC and Treg in tumor-bearing mice. We also 
examined the effect of PD-L1 blockade on PD-L1high M2 macrophages and MDSCs, and 
on activation of CD8 T cells. Tumor-specific IFN-ɣ response was also measured to 
examine long-term memory response. Overall, our results suggest the combination of 
sunitinib and PD-L1 blockade can significantly improve the therapeutic efficacy of TLR7/8 
agonist based nanovaccine. 
 
4.3. Materials and Methods 
Chemicals and reagents 
 TLR7/8 agonist 522 was synthesized and characterized as previously reported 42. 
Sunitinib and 2-mercaptoethanol were purchased from Sigma-Aldrich (St Louis, MO). 
Murine granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-4, IL-6 and 
IFN-ɣ were purchased from Peprotech (Rocky Hill, NJ). Enzyme-linked immunosorbent 
assay (ELISA) kits were purchased from Biolegend (San Diego, CA). 
 Fluorophore-labeled monoclonal antibodies for flow cytometry analysis were 
purchased from Biolegend (CD3, CD8, CD11a, CD11c, CD80, CD206, F4/80, Gr-1, PD-
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L1), eBioscience (San Diego, CA) (CD11b, CD44, CD86, Foxp3) and BD Biosciences 
(San Jose, CA) (CD4). 
 
Animals and cell line 
All the protocols involving the use of animals were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Minnesota, and 
experiments were performed accordingly. Immunocompetent C57BL/6 mice (6-9 weeks, 
female) were purchased from Charles River (Wilmington, MA) and housed in specific 
pathogen free (SPF) facilities maintained by the Research Animal Resources at the 
University of Minnesota. The murine urothelial carcinoma cell line MB49 (ATCC) was 
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 μg/mL 
streptomycin and 100 U/mL penicillin (complete RPMI). 
 
Cultivation of bone marrow-derived DCs (BMDCs) and bone marrow-derived 
MDSCs (BM-MDSCs)  
 Primary cells were isolated from tibias and femurs of mice as described previously 
70. Isolated cells were transferred to petri dishes and incubated with complete RPMI media. 
For BMDC cultivation, complete RPMI media was supplemented with 20 ng/mL GM-
CSF, 10 ng/ml IL-4 and 50 μM 2-mercaptoethanol. For BM-MDSC cultivation, 40 ng/mL 
GM-CSF and 40 ng/mL IL-6 were added to complete RPMI media as previously reported 
191. Cells were supplemented with fresh media on d 3 and harvested on d 6 for assays. 
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In vitro BMDC assays 
 BMDCs (106/well) were seeded in 24-well plates and incubated with 0.1, 1, or 10 
µM of 522 for 24 h, and cell culture supernatants were collected for ELISA. In a separate 
study, 522 (28 µM) and/or sunitinib (5 µM) were added to cells and incubated for 24 h. 
Cells were then stained with fluorophore-labeled antibodies to measure co-stimulatory 
molecule (CD80, CD86) expression on CD11c+ BMDCs by flow cytometry (BD 
LSRFortessa H0081). Cell culture supernatants were collected for ELISA. 
 
PD-L1 on MB49 cells 
MB49 cells were incubated with murine IFN-ɣ (100 ng/ml) as previously reported 
189. After 24 h, cells were collected and stained with anti-PD-L1 antibody (BioXcell, West 
Lebanon, NH) followed by a AF647-labeled secondary antibody (anti-rat IgG, Abcam, 
Cambridge, MA). PD-L1 expression on MB49 cells was measured by flow cytometry. 
 
Cytotoxicity assay 
 BMDCs and BM-MDSCs (4 x 104/well) were seeded in 96-well plates. On the same 
day, 0.78 ~ 100 µM of sunitinib or 522 were added to the cells. After 24 h, cell culture 
supernatants were collected to measure LDH release according to manufacturer’s protocol 
(LDH Cytotoxicity Assay Kit, Thermo). MB49 cells (104/well) were seeded in 96-well 
plates. Following the attachment of cells to the plate (~18 h), cytotoxicity of sunitinib and 
522 were determined as described above. 
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Ex vivo splenocyte cytokine assay 
Spleens were harvested from MB49 tumor bearing mice. Single cell suspension of 
splenocytes was prepared as previously reported 45. Briefly, spleens were mechanically 
homogenized with Hanks' Balanced Salt solution (HBSS) using gentleMACS Dissociator 
(Miltenyi BioTeck Inc., Auburn, CA). Homogenized cell suspension was washed with PBS 
and incubated in HBSS supplemented with 0.15 mg/ml DNAse I (Sigma) and 0.56 
Wuensch units/ml Liberase Blendzyme 3 (Roche, Branford, CT) in a water bath (37°C) for 
30 min. Cells were further washed with HBSS and the red blood cells were removed using 
ACK lysis buffer (Thermo). Cell suspension was washed with PBS, resuspended in 
complete RPMI and seeded in a 24-well plate (106/well). Splenocytes were then incubated 
with 522 (28 µM) and/or sunitinib (1.25, 2, 5 µM) for 24 h, and the supernatants were 
collected for ELISA. 
 
In vivo tumor model and treatments 
 MB49 cells (2 x 105) suspended in 100 µl of PBS were injected subcutaneously in 
the abdominal area of C57BL/6 mice. Treatments began when the tumors were 100~150 
mm3. Tumor dimensions were measured using digital calipers as previously reported 70.  
Mice that developed ulcerated core in the tumor or had a tumor volume greater than 1500 
mm3 were removed from the study and euthanized.  
Nanoparticles loaded with 522 (522NPs) and MB49 cell lysates were prepared as 
previously reported 70. 522NPs (2 mg/mouse, equivalent to 2 µg of 522) were combined 
with MB49 cell lysate (100 µg/mouse) in 200 µl of PBS (referred to as ‘nanovaccine’) and 
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injected subcutaneously once daily for five days. Sunitinib (10 mg/kg) was prepared in 
sterile normal saline and administered once daily by oral gavage from d 1 to the end of 
study 187,192. Anti-PD-L1 antibody (BioXcell, West Lebanon, NH) was prepared in PBS 
and a total of 3 doses (each 200 µg) were administered intraperitoneally once every three 
days 193,194.  
 
In vivo MDSC, Treg, M2 macrophage and CD8 T cell measurement 
 Tumor-bearing mice were administered various treatments as described above. 
Spleens and tumors were collected 9 days after treatment began. Single cell suspensions of 
spleen and tumor were prepared as described above and stained with fluorophore-labeled 
antibody to identify MDSC (Gr-1+CD11b+), Tregs (CD3+CD4+Foxp3+), M2 macrophages 
(CD11b+F4/80+CD206+), and CD8 T (CD3+CD8+) cells. Intracellular staining of Foxp3 
was performed according to manufacturer’s manual (Foxp3/Transcription Factor Staining 
Buffer Set, eBioscience). Cells were analyzed by flow cytometry. 
 
ELISA for tumor specific IFN-ɣ measurement 
  Splenocytes from immunized mice were seeded in a 24-well plate (5 x 106/well) 
in complete RPMI supplemented with 50 µM 2-mercaptoethanol  195. MB49 cell lysates 
(100 µg) were added to cells. After 48 h, cell culture supernatants were collected for 
ELISA.  
 
Statistical analysis 
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Results are shown as mean ± standard deviation (SD) or mean ± standard error of 
the mean (SEM) as indicated. The statistical significance of the observed differences 
between the treatment groups were determined by one-way analysis of variance (ANOVA) 
with post hoc Tukey test, unless otherwise noted. A p-value less than 0.05 was considered 
statistically significant; *p<0.05, **p<0.01, ***p<0.001. Statistical analyses were 
performed using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA).  
 
4.4. Results  
4.4.1. IL-10 secretion and PD-L1 upregulation 
 BMDCs cultured with 0.1 ~ 10 µM of 522 secreted 150 ~ 300 pg/ml of IL-10 while 
PBS treated BMDCs secreted 14 ng/ml of IL-10 (Figure 4.1A). Consistent with a previous 
study 189, we detected increased PD-L1 expression on MB49 cells when stimulated with 
IFN-ɣ (Figure 4.1B,C). Similar to that shown by others 193,194, even untimulated MB49 
cells had a moderately high basal level of PD-L1 expression.  
 
(A) 
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(B)                                                                          (C)  
 
Figure 4.1. Cytokine and PD-L1 measurement 
(A) Cell culture supernatant was collected from BMDCs incubated with PBS or 522. IL-
10 levels were measured by ELISA. Results are reported as mean  SD, N=3 (B,C) PD-L1 
expression on MB49 cells was measured by flow cytometry. (B) Representative histogram 
of fluorescence intensity. (C) Geometric MFI of AF647 was quantified. Results are 
reported as mean  SD, N=2, *p<0.05, ***p<0.001, One-way ANOVA with post hoc 
Tukey’s test  
 
 
4.4.2. Cytotoxicity assays 
 Cytotoxicity of sunitinib was examined in MB49, BM-MDSCs and BMDCs 
(Figure 4.2A). Sunitinib induced 87% and 75% cytotoxicity against MB49 cells at 100 µM 
and 50 µM, respectively. However, sunitinib had negligible cytotoxicity at lower 
concentrations (IC50 of 30 µM). Sunitinib was more cytotoxic to BM-MDSCs and BMDCs 
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(IC50 of 3.7 µM and 9.2 µM, respectively). We also tested the cytotoxicity of 522 against 
BMDCs and BM-MDSCs. 522 had negligible cytotoxicity in the 0.78 ~ 50 µM range (23% 
and 22% cytotoxicity against BMDCs and BM-MDSCs, respectively, at 100 µM) (Figure 
4.2B).  
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Figure 4.2. Cytotoxicity of sunitinib and 522 
(A) Cytotoxicity of sunitinib against MB49 cells, BM-MDSCs, and BMDCs. Results are 
reported as mean  SD, N=4 (B) Cytotoxicity of 522 was examined against BM-MDSCs 
and BMDCs. Results are reported as mean  SD, N=4. 
 
4.4.3. Ex vivo splenocytes IL-10 measurement 
Based on the cytotoxicity profiles of sunitinib and 522, we chose 28 µM of 522 and 
1.25, 2.5 and 5 µM of sunitinib for ex vivo cytokine assay. In both PBS treated and sunitinib 
treated splenocytes from MB49 tumor-bearing mice, we detected 41 pg/ml of IL-10 
(Figure 4.3A). Identical to that observed in BMDCs, 522 treatment significantly increased 
IL-10 expression (797 pg/ml) in splenocytes. However, addition of sunitinib resulted in a 
dose-dependent reduction in the amount of IL-10 produced by 522 treated splenocytes.  
 
4.4.4. Effect of sunitinib on DCs  
Consistent with Figure 4.1A, we detected high levels (603 pg/ml) of IL-10 when 
BMDCs were treated with 522 (Figure 4.3B) and negligible amount of IL-10 in PBS and 
sunitinib treated BMDCs. BMDCs treated with 522 and sunitinib showed significantly 
reduced IL-10 expression (89 pg/ml) compared to those that received only 522. We then 
investigated the effect of sunitinib on DC activation. Sunitinib alone did not activate DCs. 
However, 522 and sunitinib combination triggered increased co-stimulatory molecule 
(CD80, CD86) expression of BMDCs (Figure 4.3C). Compared to PBS treated group, 522 
treated BMDCs had 5-fold increased frequency of CD80high cells. When sunitinib was 
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added with 522, frequency of CD80high cells increased 9-fold compared to that following 
PBS treatment. CD86high cells also significantly increased from 14.7% in the PBS treatment 
group to 71% with 522 treatment and 81.4 % with sunitinib and 522 co-treatment.  
 
(A)                                                                              (B) 
 
(C) 
 
 
Figure 4.3. Cytokine assays and In vitro BMDC activation 
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(A) Splenocytes were collected from tumor-bearing mouse and incubated with 522 (28 
µM) and sunitinib (1.25, 2.5 and 5 µM). IL-10 levels were measured from cell culture 
supernatants using ELISA. Results are reported as mean  SD, N=3, One-way ANOVA 
with post hoc Tukey’s test (B) BMDCs were incubated with 522 (28 µM) and sunitinib (5 
µM). Cell culture supernatants were collected for IL-10 measurement. Results are reported 
as mean  SD, N=3, ***p<0.001, One-way ANOVA with post hoc Tukey’s test (C) Flow 
cytometry analysis of CD80 and CD86 expression on BMDCs after 24 h incubation with 
522 (28 µM) and sunitinib (5 µM). Results are reported as mean  SD, N=3, ***p<0.001, 
One-way ANOVA with post hoc Tukey’s test 
 
4.4.5. Effect of sunitinib on MDSC and Treg in vivo 
 We investigated the in vivo potency of sunitinib in reducing MDSCs and Tregs in 
the spleen and tumor. Tumor-free mice had 1.7% MDSCs in the spleen, while tumor-
bearing mice had 2.7% MDSCs (Figure 4.4A). When sunitinib was administered to tumor-
bearing animals, MDSC population reduced to 1.6%, which is similar to that in the non-
tumor bearing mice. Nanovaccine treated mice showed increased MDSCs (4.7%) in the 
spleen, but the combination of nanovaccine and sunitinib reduced the splenic MDSCs to 
2.7%. A similar trend was observed for MDSCs in the tumor, where nanovaccine treated 
animals had 5.9% MDSCs while mice that received nanovaccine and sunitinib co-treatment 
had reduced (4.9%) tumor MDSC population.  
 Similar to MDSCs, Tregs also decreased when mice were treated with a 
combination of nanovaccine and sunitinib. Frequency of Foxp3+ CD4 T cells in spleen of 
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tumor bearing mice was 12.6% compared to 9.4% in non-tumor bearing mice (Figure 
4.4B). Nanovaccine treated mice showed 11.9% of Foxp+ CD4 T cells and nanovaccine 
and sunitinib co-treatment reduced the Treg population to 10.1%. In the tumor, frequency 
of Foxp3+ CD4 T cells from untreated and nanovaccine treated animals were 29.1% and 
30.8%, respectively. Sunitinib treatment reduced the frequency of Foxp3+ CD4 T cells to 
25.9% and nanovaccine and sunitinib co-treatment further reduced this population to 
22.5%.  
 
 
 
(A) 
 
 
(B) 
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Figure 4.4. In vivo MDSCs and Tregs 
MB49 tumor-bearing mice received nanovaccine and/or sunitinib as described in the 
Methods. Spleens and tumors were collected and analyzed by flow cytometry.  (A) 
Frequency of MDSCs (Gr-1+CD11b+) in the spleen and tumor. (B) Frequency of Tregs 
(Foxp3+ of CD4 T cells) in the spleen and tumor. Results are reported as mean  SEM, 
N=4, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA with post hoc Tukey’s test  
 
 
4.4.6. In vivo PD-L1high M2 macrophage and MDSC 
 In the spleen of tumor-bearing mice, 41.6% of M2 macrophages expressed high 
level of PD-L1. Following treatment with nanovaccine and nanovaccine-sunitinib, this 
population decreased to 36.7% and 34.9%, respectively (Figure 4.5A). When PD-L1 
blockade was combined with nanovaccine, frequency of PD-L1high M2 macrophages 
decreased to 23.1%, which was similar to that following treatment with just the PD-L1 
blockade (25.5%). Animals treated with the triple combination of 
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nanovacine+sunitinib+PD-L1 blockade had the lowest frequency of PD-L1high M2 
macrophages (15.5%). M2 macrophages in the tumor (tumor-associated macrophages) also 
had high levels of PD-L1 (47.3%).  Addition of sunitinib reduced this population somewhat 
(47% vs. 41% for nanovaccine and nanovaccine+sunitinib, respectively). 
Nanovaccine+PD-L1 blockade and PD-L1 blockade alone treatments reduced the PD-
L1high M2 macrophages to 9.9% and 12.1%, respectively. Similar to that observed in the 
spleen, nanovaccine+sunitinib+PD-L1 blockade treated animals had the lowest PD-L1high 
M2 macrophages (9.4%).   
 PD-L1 expression levels on splenic MDSCs also showed similar trend as M2 
macrophages. In the untreated group, 14.4% of MDSCs expressed high level of PD-L1. 
Nanovaccine and nanovaccine+sunitinib treatments reduced PD-L1high MDSCs to 9.7% 
and 11.8%, respectively (Figure 4.5B). Nanovaccine+PD-L1 blockade and PD-L1 
blockade alone treatments reduced the PD-L1high MDSCs by 7.6 % and 8.3 %, respectively. 
However, nanovaccine+sunitinib+PD-L1 blockade treated groups showed the lowest PD-
L1high MDSCs of 4.1%, which was the only treatment that showed a statistically significant 
reduction in PD-L1 expression compared to the untreated group. In the tumor, PD-L1 
expression on MDSCs were higher than splenic MDSCs, where the untreated group had 
34% of PD-L1high MDSCs. Nanovaccine and nanovaccine+sunitinib treated groups also 
showed high frequencies of PD-L1high MDSCs of 36.9% and 37.8%, respectively. PD-L1 
blockade alone treatment reduced the PD-L1 high MDSCs to 31% while nanovaccine+PD-
L1 blockade combination reduced this to 21.4%. Lowest PD-L1high MDSCs were observed 
when animals were treated with nanovaccine+sunitinib+PD-L1 blockade (4.1%).  
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(A) 
 
(B) 
 
Figure 4.5. In vivo PD-L1high M2 macrophages and MDSCs 
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MB49 tumor-bearing mice received combination treatments consisting of nanovaccine, 
sunitinib and anti-PD-L1 antibody. Spleens and tumors were collected and analyzed by 
flow cytometry. (A) Frequency of PD-L1high M2 macrophages (CD11b+F4/80+CD206+) in 
the spleen and tumor. (B) Frequency of PD-L1high MDSCs (Gr-1+CD11b+) in the spleen 
and tumor. Results are reported as mean  SEM, N=5, *p<0.05, **p<0.01, ***p<0.001, 
One-way ANOVA with post hoc Tukey’s test  
 
 
4.4.7. In vivo CD8 T cell activation 
 Activation of CD8 T cells in the spleen and tumor was examined by measuring 
CD44 expression on CD8 T cells 196. In the spleen of untreated mice, CD44high frequency 
was 11.9% (Figure 4.6). Nanovaccine treatment increased the CD44high CD8 T cells to 
16.3% while nanovaccine+sunitinib treated animals had 15.5%. Nanovaccine+PD-L1 
blockade treatment resulted in 17.6% of CD44high CD8 T cells while PD-L1 blockade alone 
increased this population to 20.2%. Nanovaccine+sunitinib+PD-L1 blockade treatment 
increased the CD44high CD8 T cells to 19.9%. 
 In the tumor, CD44high CD8 T cells in untreated mice was 8.1% while nanovaccine 
and nanovaccine+sunitinib treatment increased this population to 10.9% and 12.4%, 
respectively. Nanovaccine+PD-L1 blockade and PD-L1 blockade alone treated animals 
had 11.1% and 14% of CD44high CD8 T cells, respectively. Highest frequency (16.2%) of 
CD44high CD8 T cells was observed in the animals treated with nanovaccine+sunitinib+PD-
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L1 blockade, which was the only treatment that showed a statistically significant increase 
compared to the untreated group. 
 
 
Figure 4.6. In vivo CD8 T cell activation and IFN-ɣ response. 
MB49 tumor-bearing mice received combination treatments consisting of nanovaccine, 
sunitinib and anti-PD-L1 antibody. Spleens and tumors were collected and analyzed by 
flow cytometry and ELISA. Spleens and tumors were collected and analyzed by flow 
cytometry. Frequency of CD44high CD8 T cells in the spleen and tumor is shown. Results 
are reported as mean  SEM, N=5. Statistical analysis indicates Untreated Vs 
Nanovaccine+sunitinib+PD-L1 blockade treatment group 
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4.4.8. Tumor specific CD8 T cell response 
 To measure tumor-specific immune response, we monitored CD11ahigh CD8low T 
cells, as these cells indicate the antigen-experienced CD8 T cells 197. In the spleens of 
untreated animals, frequency of CD11ahigh CD8low T cell was 5.4% (Figure 4.7A). When 
mice were immunized with nanovaccine, frequency of CD11ahigh CD8low T cells increased 
to 7.6% and nanovaccine+sunitinib showed similar frequency of 7.8%. However, when 
mice were immunized with nanovaccine+PD-L1 blockade, this frequency increased 2-fold 
(11.2 %) compared to that in untreated animals. PD-L1 blockade alone and 
nanovaccine+sunitinib+PD-L1 blockade also significantly increased the frequency of 
CD11ahigh CD8low T cells to ~13%. 
 We further examined tumor-specific memory response as previously reported 195. 
Splenocytes from untreated mice secreted 13 pg/ml of IFN-ɣ when stimulated with MB49 
cell lysate (Figure 4.7B). Splenocytes from nanovaccine and nanovaccine+sunitinib treat 
groups secreted 44 pg/ml and 16.5 pg/ml of IFN-ɣ, respectively. Nanovaccine+PD-L1 
blockade and PD-L1 blockade alone treated groups were characterized by significantly 
increased secretion of IFN-ɣ (110 pg/ml and 114 pg/ml, respectively). However, the 
highest IFN-ɣ response was observed from the nanovaccine+sunitinib+PD-L1 blockade 
group (325 pg/ml), which was 25-fold higher than untreated and 3-fold higher than 
nanovaccine+PD-L1 blockade group.  
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(A)                                                                                   (B)  
 
 
 
 
 
 
 
 
Figure 4.7. Antigen-specific CD8 T cell responses 
MB49 tumor-bearing mice received combination treatment consisting of nanovaccine, 
sunitinib and anti-PD-L1 antibody and spleens were analyzed using flow cytometry and 
ELISA (A) Frequency of CD11ahigh CD8low T cells in the spleen (B) Splenocytes were 
pulsed with MB49 cell lysates for 24 h. Cell supernatants were collected to measure IFN-
ɣ using ELISA. Results are reported as mean  SEM, N=5, *p<0.05, **p<0.01, 
***p<0.001, One-way ANOVA with post hoc Tukey’s test  
 
4.4.9. Tumor challenge 
 We investigated the therapeutic efficacy of nanovaccine based combination 
therapies in a murine bladder tumor model (Figure 4.8AB). When MB49 tumors became 
palpable (~d 10 after injecting the tumor cells), treatments were initiated as described 
above. We observed rapid tumor growth in untreated group, in which the average tumor 
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volume reached 1392 mm3 on d 32. Sunitinib treated animals also showed rapid tumor 
growth and had tumor volume of 1310 mm3 on d 32. Consistent with our previous study, 
nanovaccine delayed the tumor growth. Average tumor volume of nanovaccine treated 
mice was 932 mm3. However, nanovaccine+sunitinib failed to show any therapeutic 
efficacy and average tumor volume on d 32 was 1304 mm3. In contrast, nanovaccine+PD-
L1 blockade showed enhanced therapeutic efficacy than nanovaccine alone (663 mm3). In 
nanovaccine+sunitinib+PD-L1 blockade treated mice, we observed significant therapeutic 
efficacy, where 2 out of 5 mice showed complete tumor eradication at d 34. Average tumor 
volume of 3 mice on d 34 was 165 mm3. Interestingly, PD-L1 blockade alone treatment 
also showed dramatic tumor inhibition, where 3 out of 4 mice showed complete tumor 
eradication on d 34.  
 
(A) 
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(B) 
 
Figure 4.8. Tumor challenge using MB49 tumor model 
MB49 tumor-bearing mice received combination treatments consisting of nanovaccine, 
sunitinib and anti-PD-L1 antibody. Tumor volume was monitored every 2~3 days using 
digital caliper. (A) Tumor volumes of individual mice are shown (B) Average tumor 
volume of mice per treatment are shown. Results are reported as mean   SEM, N=4~5. 
Statistical analysis shown Nanovaccine+sunitinib+PD-L1 blockade treatment Vs other 
treatments, ***p<0.001, Two-way ANOVA with post hoc Tukey’s test 
 
 
4.5. Discussion 
In vivo adjuvanticity of TLR agonists is often limited by rapid clearance from the 
injection site and inefficient delivery to lymphoid organs, resulting in sub-optimal efficacy 
of cancer vaccines 76. Following S.C. injection, molecules with a molecular weight (MW) 
of 16 kDa or less or a size of 10 nm or less are preferentially absorbed by blood capillaries 
and enter the systemic circulation 61,62. Additionally, the interstitial matrix, composed of 
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adipocytes, collagen and glycosaminoglycans (GAGs), in the hypodermis can contribute 
to biodegradation of injected molecules 60. Encapsulation in polymeric NPs can protect the 
encapsulated TLR agonists from biodegradation 198. In addition, size of the NPs can be 
fine-tuned to 200~300 nm to favor lymphatic drainage 57. Due to their negative charge 53, 
PLGA NPs can rapidly pass the negatively charged interstitial matrix and drain into the 
lymphatic capillaries 199. These aspects make PLGA NPs a suitable drug delivery platform 
of TLR agonists, particularly for synthetic TLR 7/8 agonists. Unlike other TLR agonists, 
synthetic TLR7/8 agonists are soluble in organic solvents and are sparingly soluble in 
normal saline or aqueous buffers 68, which limits their systemic use 69. In our previous 
study 70, we were able to disperse PLGA NPs encapsulating TLR7/8 agonists in 
physiological saline and, could therefore combine the agonist NPs with tumor antigen in a 
single formulation for S.C. injection, which demonstrates that PLGA NPs can be suitable 
in vivo drug delivery platform of TLR7/8 agonists 
MDSCs are key immunosuppressive cells in the tumor microenvironment that 
hamper the effectiveness of cancer immunotherapy. MDSCs express arginase 1 (ARG1) 
and inducible nitric oxide synthase (iNOS), both of which can inhibit T cell activation by 
impairing T cell receptor (TCR) signaling 200. Furthermore, MDSCs secrete IL-10, which 
stimulates the induction of Tregs and deactivates T cells 201. TLR7/8 ligation can activate 
MDSCs via NF-κB signaling and by inducing IL-10 secretion from DCs 201. Thus, 
inhibition of MDSCs could be critical for the success of TLR7/8 agonist-based cancer 
immunotherapy. Sunitinib, a TKI that can selectively target signal transducer and activator 
of transcription 3 (STAT3), was utilized to eliminate MDSCs. Our results show that 
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TLR7/8 agonist triggers IL-10 secretion from splenocytes, but addition of sunitinib 
downregulates IL-10 significantly in dose-dependent manner. Based on the cytotoxicity of 
sunitinib against BM-MDSCs and BMDCs, it is possible that sunitinib selectively killed 
MDSCs and Tregs, which resulted in IL-10 reduction. In vivo studies showed that co-
treatment of sunitinib with nanovaccine reduced the MDSCs in the spleen and tumor 
compared to vaccination alone, which was consistent with previous studies 202,203. 
Furthermore, Tregs were also reduced when nanovaccine was combined with sunitinib 
treatment, which may be the consequence of sunitinib’s effect on MDSCs. These results 
suggest that low oral doses of sunitinib is sufficient to reduce immunosuppressive cells. In 
addition to regulating MDSCs, sunitinib appeared to have favorable effects on DCs. In 
addition to reducing 522-induced IL-10 secretion, sunitinib also resulted in greater 
expression of co-stimulatory molecules CD80 and CD86 on DCs. It has been reported that 
TKI alone or combination with a TLR 7 agonist can induce detrimental effects on DCs 
204,205. One key difference in our study is that 522 is a dual TLR 7/8 agonist compared to 
the TLR 7-specific ligand used in the prior study. Pre-treatment of DCs with sunitinib can 
induce TH1 phenotype and downregulate TH2 phenotype 206, suggesting that sunitinib not 
only eliminates MDSC, but can also augment TH1 response. 
PD-L1 is a inhibitory molecule expressed on various cells including tumor cells, 
monocytes, and macrophages 9. PD-L1 can impair anti-tumor immune responses by 
inducing apoptosis, anergy and exhaustion of effector CD8 T cells and NK cells 13. 
Consequently, PD-L1 expression is associated with poor prognosis in various tumors and, 
thus considered as a predictive marker of cancer immunotherapy 12. Paradoxically, IFN-ɣ, 
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which enhances cancer immunotherapy by stimulating antigen-presenting machinery and 
sensitizing tumor cells to express MHC I, is a main inducer of PD-L1 upregulation on 
tumor cells 207. As TLR agonists induce activation of CD8 T cells and NK cells that secrete 
IFN-ɣ, modulation of PD-L1high suppressive cells can be beneficial for TLR7/8 agonist-
based nanovaccine. In this regard, we combined PD-L1 blocking antibody with 
nanovaccine and investigated the efficacy of the combination in reducing PD-L1 
expressing cells and augmenting CD8 T cell immunity. Interestingly, combination of 
sunitinib and nanovaccine did not downregulate PD-L1high M2 macrophages, the triple 
combination of nanovaccine+sunitinib+PD-L1 blockade resulted in greater reduction of 
PD-L1high splenic M2 macrophages compared to nanovaccine+PD-L1 blockade. This 
points to potential synergies between the three treatments. In the tumor, 
nanovaccine+sunitinib+PD-L1 blockade significantly reduced PD-L1high M2 
macrophages. A previous study reported that combination of TLR7 agonist with PD-1 
blocking antibody polarizes immunosuppressive M2 macrophages to M1 phenotype in the 
tumor 134, which is similar to what we observed. In addition, nanovaccine+sunitinib+PD-
L1 blockade significantly reduced PD-L1high MDSCs 208 in the spleen and tumor. 
Interestingly, although sunitinib treatment reduced MDSCs and Tregs, it did not 
downregulate PD-L1 expression on MDSCs and M2 macrophages. Therefore, combining 
PD-L1 blockade with sunitinib can further neutralize immunosuppressive cells 209 and 
enhance the therapeutic efficacy of nanovaccine. 
To determine whether inhibiting immunosuppressive cells leads to enhanced T cell 
response, we examined CD8 T cells in the spleen and tumor. CD44high CD8 T cells were 
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investigated as these cells are in an activated state and can become memory cells 196. In the 
spleen, nanovaccine+sunitinib+PD-L1 blockade treatment increased CD44high CD8 T cells 
compared to nanovaccine and nanovaccine+sunitinib treatments, but PD-L1 blockade 
alone and nanovaccine+PD-L1 blockade also showed similar CD8 T cell activation 
potency. However, in the tumor, only nanovaccine+sunitinib+PD-L1 blockade treatment 
promoted CD44 upregulation of CD8 T cells. These results suggest that PD-L1 blockade 
can lower the T cell exhaustion and augment overall T cell activation, but downregulation 
of MDSCs and Tregs is required to promote CD8 T cell activation in the tumor. Antigen-
specific CD8 T cell responses were further examined to determine long-term memory 
response. Consistent with our previous study 70, nanovaccine increased CD11ahigh CD8low 
T cells in the spleen. While we detected no synergetic effect of sunitinib and nanovaccine, 
PD-L1 blockade alone significantly increased CD11ahigh CD8low T cells as single or 
combination therapy with nanovaccine and sunitinib. IFN-ɣ production showed a similar 
trend, where splenocytes from PD-L1 blockade alone and nanovaccine+PD-L1 blockade 
treated mice responded well to MB49 cell lysates. Interestingly, although 
nanovaccine+sunitinib+PD-L1 blockade induced similar induction of CD11ahigh CD8low T 
cells as PD-L1 blockade alone and nanovaccine+PD-L1 blockade, IFN-ɣ response was 3-
fold greater than both treatments, which implies that nanovaccine+sunitinib+PD-L1 
blockade treatment is effective in generating antigen-specific CD8 T cells and inducing 
long-term memory response.   
Consistent with our previous study, nanovaccine was effective in delaying tumor 
growth compared to the untreated group. However, addition of sunitinib to nanovaccine 
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did not show any therapeutic advantages over nanovaccine treatment, which can be 
explained by the fact that sunitinib reduced MDSCs and Tregs, but did not directly promote 
CD8 T cell activation. Nanovaccine+PD-L1 blockade showed enhanced therapeutic 
efficacy compared to nanovaccine alone, which implies that promoting CD8 T cell 
response by blocking PD-L1/PD-1 signaling can enhance nanovaccine efficacy. We 
observed significant tumor regression from nanovaccine+sunitinib+PD-L1 blockade 
group, which demonstrates that eliminating MDSCs and Tregs as well as blocking PD-
L1/PD-1 signaling promotes antigen-specific CD8 T cells and results in potent anticancer 
immunotherapy. Interestingly, PD-L1 blockade alone treated groups also showed 
significant therapeutic efficacy. Unlike TLR 7/8-based nanovaccine, PD-L1 blockade  
alone treatment does not stimulate immune-suppressive cell activation 210,211, which can 
explain the superior therapeutic efficacy of PD-L1 blockade alone treatment compared to 
nanovaccine+PD-L1 blockade. However, PD-L1 blockade alone treatment does not elicit 
long-term memory response, and previous studies report the development of resistance 
11,212, which makes it a sub-optimal therapeutic for long-term therapy. Potent antigen-
specific memory response induced by nanovaccine+sunitinib+PD-L1 blockade points to 
its potential for inducing long-term tumor growth inhibition.  
In this study, we demonstrate that daily oral dosing of sunitinb reduces MDSCs and 
Tregs, and PD-L1 blockade further neutralizes PD-L1high M2 macrophages and MDSCs. 
We also observed potent activation of antigen-specific CD8 T cells and induction of 
memory response. Combined, our results suggest that combination of sunitinib and PD-L1 
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blockade can modulate the tumor microenvironment and enhance the anticancer efficacy 
of TLR7/8 agonist-based nanovaccine. 
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Chapter 5. 
 
 
TLR7/8 agonist encapsulating polymeric 
nanoparticles can promote NK cell activation  
and augment antibody-based cancer 
immunotherapy 
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5.1. Summary 
 
Natural killer (NK) cells are cytotoxic cells that upon activation can kill malignant 
tumor cells via granule exocytosis and secrete IFN-ɣ, a key regulator of TH1 response. 
Thus, mobilization of NK cells can augment cancer immunotherapy, particularly mediated 
via antibody-dependent cellular cytotoxicity (ADCC). In the current study, we investigated 
synthetic toll-like receptor (TLR) 7/8 agonists to activate NK cells. TLR7/8 ligation of 
dendritic cells (DCs) promote NF-κB-mediated pro-inflammatory cytokine secretion and 
co-stimulatory molecule upregulation, both which potentiate NK cell activation. To enable 
subcutaneous delivery to antigen presenting cells, we encapsulated the agonists in 
polymeric nanoparticles (NPs). NP-encapsulated agonist induced enhanced co-stimulatory 
molecule expression on DCs and stronger pro-inflammatory cytokine response, compared 
to the soluble agonist. When injected into immunocompetent mice, NK cells from NP 
treated mice showed stronger cytotoxicity and prolonged activation compared to those 
from soluble agonist treated group. TLR7/8 agonist loaded NPs potentiated stronger NK 
cell degranulation, which resulted in enhanced ADCC efficacy of epidermal growth factor 
receptor (EGFR) targeting monoclonal antibody, cetuximab. These results suggest NPs 
encapsulating TLR7/8 agonist could be used as a potent immunostimulatory adjuvant for 
antibody-based cancer immunotherapy by promoting NK cell activation. 
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5.2. Introduction 
 Monoclonal antibodies targeting specific tumor cell surface receptors such as 
epidermal growth factor receptor (EGFR) and HER-2 are immunotherapeutics approved 
for the treatment of various solid tumors 6,213. In addition to their direct inhibitory effects 
on these receptors, the antibodies also elicit natural killer (NK) cell-mediated antibody-
dependent cell cytotoxicity (ADCC) responses to kill the tumor cells 5.  
NK cells play multiple roles in cancer immunotherapy. NK cells can recognize and 
kill the tumor cells that are MHC I-deficient as well as those labeled by complement or 
antibodies via granule exocytosis 214. In addition, NK cells secrete interferons that activate 
other immune cells including dendritic cells (DCs), B cells and T cells, which demonstrate 
their versatility in cancer immunotherapy 215.  Thus, stimulation of NK cells can augment 
therapeutic efficacy of antibody-based cancer immunotherapy. 
Small molecules including toll-like receptor (TLR) agonists 216, lenalidomide 217, 
erlotinib 218, and NKG2D receptor ligands including histone deacetylase (HDAC) 
inhibitors 219 and retinoic acids 220 have been shown to activate NK cells and augment 
ADCC. Pro-inflammatory cytokines including IL-2, 12, 15, 18, IFN-ɑ and IFN-ɣ are also 
modulators of NK cell activation 221. As TLR agonists can stimulate diverse subsets of DCs 
to secrete pro-inflammatory cytokines and type I interferons 222, various TLR agonists 
including polysaccharide krestin (PSK; TLR2), polyinosinic:polycytidylic acid (poly I:C; 
TLR3),  CpG oligodeoxynucleotides-derivatives (CpG; TLR9) have been shown to 
potentiate ADCC response in both pre-clinical and clinical studies 223–225.  
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Imidazoquinoline-based synthetic TLR7/8 agonists are potent pro-inflammatory 
cytokine inducers 35, and thus have the potential to improve the effectiveness of antibody-
based cancer immunotherapy. Previously, our group reported a novel TLR7/8 agonist 
(termed ‘522’), which induces secretion of IL-12, IL-1β, TNF-α and IFN-ɣ from human 
peripheral blood mononuclear cells (PMBCs) 42, and upregulates co-stimulatory molecules 
expression on murine DCs. pointing to its potential as an NK cell stimulant. To enable in 
vivo use, we encapsulated the TLR7/8 agonist in an acid pH-responsive poly(lactide-co-
glycolide) (PLGA) nanoparticles (NPs) 70. In our previous study 70, we observed pH 
responsive agonist release and robust DC maturation and NK cell activation. In the present 
study, we investigated whether NP-encapsulated agonist can enhance ADCC against 
EGFR+ human lung carcinoma using EGFR targeting monoclonal antibody, cetuximab 5. 
Our results demonstrate that NPs encapsulating TLR7/8 agonist could be used as a potent 
immunostimulatory adjuvant for enhancing antibody-based cancer immunotherapy. 
 
 
5.3. Materials and Methods 
Chemicals and reagents 
 TLR7/8 agonist ‘522’ and polymeric nanoparticle encapsulating 522 (522GGNP) 
were prepared as previously described 42. Polyinosinic:polycytidylic acid (poly I:C) and 
sterile  dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St Louis, MO). 
Brefeldin A solution (BFA), carboxyfluorescein succinimidyl ester (CFSE) cell division 
tracker kit and fluorophore labeled antibodies (CD3, CD25, CD49b, CD56, CD69, 
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CD107a, IFN-ɣ, granzyme B) were purchased from Biolegend (San Diego, CA). 
Cetuximab was purchased from Merck KGaA (Darmstadt, Germany). 
 
Animals and cell line 
 Athymic nude mice and TAP1-deficient (Tap1tm1Arp) mice were purchased from 
Jackson Laboratories (Bar Harbor, ME). C57BL/6 mice were purchased from Charles 
River (Wilmington, MA). All mice were female and 6-7 weeks old at the time of arrival.  
A549 cell line was purchased from ATCC. Cells were cultured in RPMI 1640 
medium which contain fetal bovine serum, 100 μg/mL streptomycin, 100 U/mL penicillin 
(hereafter referred to as complete RPMI). 
 
Bone marrow derived dendritic cells (BMDCs) activation and cytokine assay 
 BMDCs were cultured as previously reported 70 and one million BMDCs were 
plated in 24-well plate.  Poly I:C (0.2 µg/ml), soluble form of 522 in DMSO (Free522)(0.2 
µg/ml) and 522GGNPs (0.2 µg/ml of 522 equivalent) were added to the cells and incubated 
overnight. Next day, cells were harvested and pelleted down. Supernatants were collected 
and IL-12p70 was quantified by ELISA kit (Biolegend). Pelleted cells were washed and 
stained with fluorophore labeled antibody to measure co-stimulatory molecule expression 
(CD70, CD80, CD86) by flow cytometry (LSRFortessa H0081, BD Bioscience). 
 
Cytokine and NK cell activation assay 
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 Human peripheral blood mononuclear cells (PBMCs) were harvested from blood 
obtained from healthy donors. Heparinized blood was processed with standard density-
gradient centrifugation using Ficoll-Paque media (GE healthcare). PBMCs (5 x 
105 cells/well) were seeded at 24-well plate. Treatments used for BMDC assay were 
prepared at 10 µg/ml concentration and incubated with PBMCs for 18 h. After 18 h, cell 
culture supernatants were collected to measure IL-12p70 (Biolegend) and IL-18 
(Raybiotech, Norcross, GA) using ELISA. 
 In a similar but separate experiment, BFA was added to the PBMCs for additional 
6 h. Collected PBMCs were washed and stained with anti-CD3, anti-CD56, anti-CD25 and 
anti-CD69 antibodies (Biolegend). Intracellular IFN-γ staining was performed according 
to the manufacturer’s protocol (Foxp3/Transcription Factor Staining Buffer Set, 
eBioscience). Stained cells were analyzed using flow cytometry. 
 
In vivo NK cell cytotoxicity assay 
 NK cell cytotoxicity was evaluated as previously described 226. Spleens were 
collected from C57BL/6 and TAP1 (Tap1tm1Arp)-deficient mice and were used to prepare 
single cell suspensions as previously reported 70. Splenocytes from C57BL/6 and TAP-
deficient mice were each labeled with 7 µM and 0.7 µM of CFSE, respectively. After 
staining, equal number of splenocytes from both mice were mixed and injected (total 1 x 
107 cells) to recipient C57BL/6 mice via intravenous (I.V.) injection.  Mice were then 
randomized and received different treatments. Free522 and 522GGNP (40 µg equivalent 
amount of 522) were prepared in PBS and injected subcutaneously (S.C.) in recipient mice. 
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After 18 h, spleens were harvested from recipient mice. Processed splenocytes were 
analyzed by flow cytometry to measure CFSElow (TAP1-deficient, target) to CFSEhigh 
(C57BL/6, control) ratio to determine in vivo NK cell cytotoxicity.  
 
In vivo NK cell activation assay 
 Free522 and 522GGNP (40 µg equivalent amount of 522) were prepared in PBS 
and injected S.C. in C57BL/6 mice. After 3 d, spleens were harvested and single cell 
suspension of splenocytes were prepared as previously reported 70.  Cells were then stained 
with anti-CD3, anti-CD49b, anti-CD69 antibodies and intracellular staining of granyme B 
was performed as described above. 
 
NK cell degranulation and T cell activation assay with cetuximab 
 NK cell degranulation assay was performed as previously reported 223,227. Briefly, 
human PBMCs were treated with poly I:C, Free522 and 522GGNP as described above. 
After 18 h incubation, A549 cells (2.5 x 105 cells/well) and cetuximab (10 µg/ml) were 
added to the wells. Anti-CD107a antibody was then added to each well and after 1 h, BFA 
was added to the cells. After 6 h of incubation, cells were collected and stained with anti-
CD3, anti-CD56 antibodies to label NK cells, and intracellular staining of IFN-γ and 
granzyme B was performed as described above. In a separate study, we stained the cells to 
label CD4 (CD3+CD56-CD4+) and CD8 (CD3+CD56-CD8+) T cells and determined the T 
cell activation by measuring CD69.  
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Antibody-dependent cell cytotoxicity (ADCC) 
 ADCC assay was performed as previously reported 224. Briefly, human PBMCs 
were incubated with treatments as described above for 18 h, and used as effector cells. 
After 18 h, A549 cells were incubated with cetuximab (100 nM) for 1h. Effector PBMCs 
and cetuximab treated A549 cells (target cells) were seeded in 96-well plates in various 
effector to target (E:T) ratios and incubated overnight. The next day, supernatants were 
collected and cellular cytotoxicity was measured by LDH assay (Thermo) according to the 
manufacturer’s protocol.  
 
Statistical analyses 
Results were reported as mean ± standard error of the mean (SEM) or mean ± 
standard deviation (SD). Statistical difference between the groups were analyzed by one-
way analysis of variance (ANOVA), with a post hoc Tukey test. Data was analyzed using 
GraphPad 7 software (GraphPad software, La Jolla, CA). P-value less than 0.05 was valued 
as statistically significant; *p<0.05, **p<0.01, ***p<0.001, n.s = not significant (p>0.05). 
 
 
5.4. Results  
5.4.1. In vitro BMDC activation 
 We investigated the extent to which 522GGNP can induce DC maturation to 
express co-stimulatory molecules and secrete pro-inflammatory cytokines. TLR3 agonist 
poly I:C was utilized as a positive treatment in our studies, as previous studies report its 
strong potency to augment ADCC 224,227.  Similar to TLR7/8 agonist 522, poly I:C ligates 
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endo/lysosome-located TLR3, but triggers TRIF signaling pathway (TLR7/8: MyD88 
signaling), which makes it an interesting control treatment. When treated with equimolar 
concentrations, Free522 increased co-stimulatory molecule relative to that with poly I:C 
and 522GGNP treated BMDCs showed greater DC activation than Free522 (Figure 5.1A). 
CD70 expression increased from 6.5% for PBS treatment to 41% for 522GGNP treatment, 
while poly I:C and Free522 resulted in 9.8% and 20%, respectively. CD80 expression also 
increased from 12% for PBS treatment to 54% for 522GGNP treatment. Poly I:C and 
Free522 treatment induced 17% and 41% expression of CD86, respectively. We detected 
dramatic upregulation of CD86 on BMDCs treated with Free522 (73%) compared to PBS 
(15%) and poly I:C (27%) treatments. However, the highest CD86 expression was achieved 
with 522GGNP treatment (89%). In addition to co-stimulatory molecule upregulation, we 
also monitored increased pro-inflammatory cytokine secretion by 522GGNP (Figure 
5.1B). While PBS and poly I:C treated BMDCs did not have detectable levels of cytokines, 
we observed significant expression of IL-12p70 following Free522 treatment and even 
higher levels with 522GGNP treatment.  
 
(A) 
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(B) 
 
Figure 5.1. In vitro BMDC activation 
BMDCs  were incubated with treatments for 24 h. Cells were then analyzed by flow 
cytometry and cell culture supernatants were analyzed by ELISA (A) Flow cytometry 
analysis of CD70, CD80 and CD86 expression on CD11c+ BMDCs. Results are reported 
as mean  SD, n=3, **p<0.01, ***p<0.001, One-way ANOVA. (B) IL-12p70 levels were 
measured from cell culture supernatants using ELISA. Results are reported as mean  SD, 
n=3, *p<0.05, **p<0.01, One-way ANOVA  
 
5.4.2. Human PBMC cytokine assay 
 As pro-inflammatory cytokines secreted from DCs are key soluble factors in 
activating NK cells 228, we investigated whether 522GGNP treatment can trigger IL-12p70 
and IL-18 secretion from human PBMCs (Figure 5.2). Consistent with the data shown in 
Figure 5.1B, Free522 also induced IL-12p70 secretion (20 pg/ml) from human PBMCs, 
but 522GGNP treated PBMC showed significantly higher level of IL-12p70 (78 pg/ml) 
  134 
than poly I:C and Free522. 522GGNP also induced significant IL-18 secretion (144 pg/ml) 
relative to poly I:C and Free522 (36 pg/ml and 80 pg/ml, respectively). 
 
 
Figure 5.2. Human PBMC cytokine assay 
Human PBMCs were incubated with treatments for 24 h. IL-12p70 and IL-18 levels in the 
cell culture supernatants were determined by ELISA. Results are reported as mean  SD, 
n=3, ***p<0.001, One-way ANOVA. 
 
 
5.4.3. In vitro NK cell activation assays 
 We further investigated whether 522GGNP is effective in activating NK cells by 
measuring NK cell activation markers (CD25, CD69) and IFN-ɣ using human PBMCs 229. 
CD25 expression increased significantly when treated with 522GGNP (27%) compared to 
PBS treatment (1.2%). Poly I:C and Free522 also increased CD25 expression by 11% and 
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20%, respectively (Figure 5.3A).   Poly I:C increased CD69 expression from 15% 
observed for PBS treatment to 70%. However, Free522 and 522GGNP were more effective 
in increasing the CD69 expression (89% and 85%, respectively) (Figure 5.3B). Consistent 
with CD25 and CD69 expression, 522GGNP was most effective in triggering IFN-ɣ 
expression of NK cells (Figure 5.3C). IFN-ɣ expressing NK cells increased from 13% with 
vehicle treatment to 41% when treated with 522GGNP. Poly I:C and Free522 treated NK 
cells each resulted in 22% and 31% IFN-ɣ positive NK cells, respectively.  
(A)                                                          (B)                                                              (C) 
 
Figure 5.3. In vitro NK cell activation assay 
Human PBMCs were incubated with treatments for 24 h and  NK (CD3-CD56+) cells were 
analyzed by flow cytometry. (A) Frequency of CD25high NK cells. (B) Frequency of 
CD69high NK cells. (C) Frequency of IFN-ɣ+ NK cells. Results are reported as mean  SD, 
n=3, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA.  
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5.4.4. In vivo NK cell cytotoxicity 
 To assess the ability of 522GGNP to trigger in vivo NK cell cytotoxicity, 
splenocytes from TAP-deficient mice, which lack MHC I, were utilized. As seen in Figure 
5.4A,B, untreated mice were only partially able to kill the target MHC I deficient 
splenocytes, resulting in a C57BL/6 (control; C) to TAP-deficient (Target; T) ratio of 3.7. 
When mice were treated with Free522, C:T ratio increased to 8.9. 522GGNP treatment was 
most effective as T:C ratio increased to 15.7, which demonstrates highly target-specific 
lysis by NK cells. 
 Activation of NK cells was investigated 3 d after a single dose immunization to 
assess long-term efficacy of 522GGNP. CD69 expression on NK cells in untreated and 
Free522 treated mice were 10.2% and 10.7%, respectively. However, 522GGNP treated 
mice showed 12.9% activation of CD69 (Figure 5.4C). Granzyme B expressing NK cells 
showed similar trend where untreated and Free522 treated groups had 8.4% and 8.5%, 
respectively, while 522GGNP treatment resulted in 11 %.  
 
(A)                                                                                                                    (B) 
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(C) 
 
Figure 5.4. In vivo NK cell assays 
(A-B) In vivo NK cell cytotoxicity assay – Recipient mice were injected with splenocytes 
stained with CFSE and were immunized immediately. (A) Representative flow cytometry 
plots for splenocytes from TAP-deficient mice (CFSEhigh, target cells) and 
immunocompetent C57BL/6 mice (CFSElow, control cells) (B) Ratio of number of CFSElow 
cells (C) to CFSEhigh cells (T) in the spleen of the receiver mice. Results are reported as 
mean  SEM, n=4~5, **p<0.01, ***p<0.001, One-way ANOVA. (C) In vivo NK cell 
activation assay – Mice were euthanized 3 d after immunization and spleens were 
collected. Frequency of CD69high NK (CD3-CD49b+) cells and GranzymeB+ NK cells are 
shown. Results are reported as mean  SEM, n=4, *p<0.05, One-way ANOVA. 
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5.4.5. NK cell degranulation assay with cetuximab 
 As combined data demonstrate that 522GGNPs can efficiently activate NK cells 
both in vitro and in vivo, we investigated the potency of 522GGNP as vaccine adjuvant to 
enhance efficacy of therapeutic monoclonal antibodies.  
NK cells release cytotoxic granules including perforin and granzyme to lyse target 
cells 230,231, which suggest that degranulation of NK cells is closely associated with 
cytotoxicity of NK cells. CD107a is a lysosomal membrane protein and considered a 
functional marker for NK cell degranulation 232,233. Therefore, CD107a+GranzymeB+ NK 
cells were analyzed to examine NK cell cytotoxicity for ADCC. Compared to untreated 
PBMCs, we detected increased NK cell degranulation when A549 cells were co-incubated 
with PBMCs, which implies that NK cells undergo degranulation when they encounter 
foreign cells (Figure 5.5A). NK cell degranulation significantly increased to 16% when 
cetuximab was added, compared to 5% in untreated group. Addition of Free522 further 
increased the NK cell degranulation to 27%, but 522GGNP treatment increased 
degranulated NK cell frequency to 32%, which is a 2-fold increase compared to cetuximab 
alone treatment. IFN-ɣ expressing NK cells also showed a similar trend. Cetuximab 
increased the frequency of IFN-ɣ expressing NK cells to 20% compared to 7% in the 
untreated group (Figure 5.5B). Free522 treated NK cells showed higher IFN-ɣ (30%) than 
cetuximab alone and 522GGNP further increased IFN-ɣ positive cells to 33%.  
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(A)                                                                                                   (B) 
 
(C) 
 
 
Figure 5.5. NK cell degranulation and T cell activation 
Human PBMCs (P) were incubated with A549 (A) cells and other treatments for 24 h. NK 
cell degranulation was analyzed by flow cytometry. (A) Frequency of 
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CD107a+GranzymeB+ NK cells. (B) Frequency of IFN-ɣ+ NK cells. Results are reported 
as mean  SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA. (C) CD4 
(CD3+CD56-CD4+) and CD8 T cells (CD3-CD56-CD8+) were analyzed by flow cytometry. 
Frequency of CD69high T cells are shown. Results are reported as mean  SEM, n=2, 
***p<0.001, One-way ANOVA. 
 
5.4.6. T cell activation assay with cetuximab 
 In addition to NK cell activation, we examined if 522 treatment can stimulate T cell 
activation. CD69, an early leukocyte activation molecule 234 was measured to determine 
the T cell activation (Figure 5.5C).  Interestingly, CD69 was downregulated (1.3 %) when 
PBMCs were co-incubated with A549 cells, compared to PBMC alone group (7.8 %). 
Cetuximab treated CD4 T cells also showed low CD69 expression (1. 5%). However, 
addition of Free522 (10 µM) significantly increased the CD69high CD 4 T cells (39 %). 
CD8 T cells showed similar trend, where PBMC only groups showed negligible CD69 
expression on CD8 T cells (4.4 %). PMBCs incubated with A549 and A549+cetuximab 
also had low CD69high CD 8 T cells (3.4 % and 4 %, respectively). Similar to CD4 T cells, 
522 significantly stimulated the CD8 T cell activation (39.9 %).  
 
5.4.7. ADCC 
 We evaluated whether enhancement of NK cell degranulation and IFN-ɣ secretion 
induced by 522GGNP treatment can result in enhanced ADCC efficacy with cetuximab. 
Compared to cetuximab alone, both Free522 and 522GGNP improved the cytotoxicity of 
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cetuximab against A549 cells (Figure 5.6). At an effector to target (E:T) ratio of 10:1, 
cetuximab treatment resulted in 17% cell kill, while Free522 and 522GGNP treatments 
increased the cytotoxicity to 21% and 26%, respectively. At an E:T ratio of 20:1, cetuximab 
treatment induced 17% cytotoxicity, which was similar to 10:1 ratio. However, Free522 
and 522GGNP treatment significantly increased the cytotoxicity to 45 % and 41 %, 
respectively.  
 
 
 
Figure 5.6. ADCC 
Human PBMCs were incubated with A549 cells pre-labeled with cetuximab. ADCC was 
measured by LDH assay. Results are reported as mean  SD, n=4, Statistical analysis for 
cetuximab alone Vs cetuximab+522GGNP treatment group. **p<0.01, ***p<0.001, One-
way ANOVA. 
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Discussion 
Despite their ability to effectively eliminate target cells, application of NK cells for 
cancer immunotherapy has been limited by their inability to recognize some tumor cells as 
well as their insufficient activation at the tumor site.  Unlike CD8 T cells that selectively 
respond to antigens via major histocompatibility complex (MHC) I restriction, NK cells 
lack antigen-specificity and respond to MHC I-deficient cells 235. However, tumors are 
highly heterogeneous and can exploit MHC I-signaling ligands including HLA-G and 
HLA-E to avoid the recognition 236. Additionally, tumors secrete immune suppressive 
cytokines and ligands that neutralize NK cell stimulatory receptor NKG2D to impair NK 
cells 182.  
Combination of tumor-targeting monoclonal antibodies and TLR7/8 agonist-
induced activation can overcome some of the above challenges. Upon antibody binding to 
the tumor cells, NK cells can bind to Fc portion of the antibodies via its CD16 receptor 237. 
This binding triggers NK cells to secrete IFN-ɣ and upregulate cytotoxic granules 238, 
which suggest that monoclonal antibodies can enhance tumor recognition by NK cells and 
mobilize NK cells to kill the tumor cells. Furthermore, TLR7/8 agonist can further augment 
ADCC by promoting NK cell activation indirectly by stimulating DC maturation. A 
previous study also suggests potential direct NK cell activation by TLR7/8 agonists 128.  
DCs are the main modulators of NK cell activation. DC-NK cell contact signaling 
via co-stimulatory molecules and pro-inflammatory cytokines can induce NK cell mediated 
IFN-ɣ and ADCC responses 222. In this study, we observed that TLR7/8 agonist 522 
upregulates CD70 and CD80/86 on murine BMDCs, which ligate CD27 and CD28, 
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respectively, to stimulate NK cell activation 173. In addition to co-stimulatory molecule 
expression, we observed upregulation of pro-inflammatory cytokines with 522 treatment. 
IL-12, a key promoter of NK cell activation 228, significantly increased with 522 treatment 
in both murine BMDCs and human PBMCs. We also observed increased IL-18 secretion 
from 522 treated human PBMCs. Previous studies report the synergetic effect of IL-12 and 
IL-18 in increasing IFN-ɣ production and consequent improvement in cytotoxicity of NK 
cells 228,239. Interestingly, 522GGNP treatment triggered stronger immunostimulatory 
responses than Free522 in both BMDC and human PBMC assays. This is consistent with 
our previous study 70, where we observed that nanoparticle-encapsulated TLR7/8 agonist 
demonstrate superior in vitro DC maturation compared to the soluble form.  
Activation associated markers CD25 and CD69 229,240 were examined to investigate 
the extent to which 522-mediated DC maturation leads to NK cell activation. We observed 
drastically increased expression of CD25 on NK cells treated with both Free522 and 
522GGNP, compared to PBS and poly I:C treatments. CD69 expression also significantly 
increased with both Free522 and 522GGNP treatment. As upregulation of CD25 and CD69 
is associated with NKG2D activation 241, these results imply that TLR7/8 agonist can 
promote NK cell activation and cytotoxicity levels. Increased IFN-ɣ expression by 522-
stimulated NK cells further demonstrates the potency of 522 for activating NK cells. 
 To determine in vivo efficacy of TLR7/8 agonist, we performed in vivo NK cell 
cytotoxicity assay using TAP-1 deficient mice model. Consistent with a previous study 226, 
we observed highly selective lysis of TAP-deficient cells even in the untreated group. 
Free522 treated animals showed enhanced cytotoxicity against target cells. In our study, 
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522GGNP treatment was highly effective in potentiating in vivo NK cell cytotoxicity 
compared to Free522, which demonstrates the advantage of nanoparticulate delivery of 
TLR7/8 agonist. Previous studies report that upon SC injection, small molecules with 
molecular weight of 16 kDa or less and/or size smaller than 10 nm, are rapidly cleared from 
the injection site either via drainage into the systemic circulation and through phagocytosis 
mediated by monocytes and macrophages 60,62. Thus, a reasonable explanation for the 
stronger in vivo NK cell cytotoxicity with 522GGNPs is their ability to protect TLR7/8 
agonist from rapid clearance and/or degradation at the injection site and to improve the 
delivery of the agonist to draining lymph nodes 61. We also observed prolonged NK cell 
activation in mice treated with 522GGNPs compared to those treated with Free522. 
Together, these results suggest that nanoparticulate delivery will enhance the in vivo 
potency of TLR7/8 agonist. 
 ADCC studies showed that NK cell degranulation increased when PBMCs were 
incubated with A549 cells, which can be explained by partial NK cell degranulation against 
MHC I-deficient A549 cells. Consistent with previous studies, cetuximab alone induced 
enhanced NK cell degranulation compared to untreated NK cells, which may have resulted 
from CD16 ligation of cetuximab 242. Co-treatment with 522GGNP significantly increased 
NK cell degranulation and IFN-ɣ production than cetuximab alone. Consistent with this 
data, 522GGNP co-treatment enhanced cetuximab-mediated ADCC against the tumor 
cells.  
 Several approaches have previously been examined to utilize NK cells for cancer 
immunotherapy. NK cells engineered to express chimeric antigen receptor (CAR) that 
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targets CD19, CS-1 and EGFR have been reported and shown to selectively kill the 
malignant tumor cells 243,244. Bi-and tri-specific killer cell engagers (BiKEs, TriKEs) that 
bridge NK cell activation moieties including CD16, IL-15, and tumor-specific antigens 
(CD33, CD133) have shown to direct NK cells to tumor sites and induce cytotolysis of 
tumors 245. Results of these studies imply that enhancing tumor cell recognition and 
activation of NK cells is critical for NK cell-mediated cancer immunotherapy. Therefore, 
combination of a therapeutic antibody and TLR7/8 agonist can be a potent 
immunotherapeutic to mobilize NK cells for cancer immunotherapy. 
 In addition to activating NK cells, TLR7/8 agonist can augment antibody-based 
cancer immunotherapy by their ability to elicit CD8 T cell immunity. Previous studies 
report that therapeutic efficacy of monoclonal antibodies is dependent on both innate and 
adaptive immunity 246, which suggest the importance of exploiting both NK cells and CD8 
T cells. Combination of therapeutic antibodies and TLR agonists have shown to enhance 
not only NK cell activation, but also trigger the priming of antigen-specific CD8 T cells 
242,247. We also observed in our study that 522 treatment significantly upregulated CD69 on 
CD4 and CD8 T cells, which is consistent with previous findings. In our previous study, 
522GGNP immunization triggered expansion of effector CD8 T cells, which further 
demonstrates the versatility of 522GGNP to promote both ADCC and CD8 T cell responses 
that can enhance anti-tumor efficacy of therapeutic antibodies.  
In summary, we demonstrated the use of pH responsive nanoparticles encapsulating 
a potent TLR 7/8 agonist to activate NK cells for antibody-based cancer immunotherapy. 
Nanoparticle-encapsulated agonist augmented ADCC with cetuximab and demonstrated 
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superior in vivo NK cell activation efficacy over the free drug. Based on these results, we 
expect broad application of 522GGNPs as immunostimulatory adjuvant for combination 
therapies with checkpoint inhibitors 248, chemotherapeutics 249, and radiation therapies 195. 
As the biocompatibility and safety profile of PLGA is well established 151, elucidating the 
pharmacokinetics of 522 after SC injection and potential adverse effects including systemic 
cytokine storm and auto-immunity will allow successful clinical translation of 522GGNPs. 
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Chapter 6. 
 
 
Summary  
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Cancer immunology and immunotherapy is a highly complexed field, involving 
interrelated response where a single component modification can affect the overall immune 
response. Therefore, selective ligation of target cells is critical to promote anti-cancer 
immunity and to reduce undesired adverse effects. In this study, we used PLGA NPs as a 
drug delivery platform for TLR7/8 agonists. We demonstrated the advantages of PLGA 
NPs nanoparticulate delivery compared to soluble form of 522 to activate DCs using a 
novel TLR7/8 agonist 522 to elicit CD8 T cell response by performing in vitro DC assays, 
in vivo T cell assays and multiple tumor challenge studies with different vaccine designs 
and modalities. We then developed pH-responsive PLGA NP that potentiated stronger T 
cell immunity than conventional PLGA NPs. Modulation of tumor microenvironment by 
co-treatment of sunitinib and PD-L1 blockade significantly enhanced therapeutic efficacy 
of 522NP-based vaccine. Additionally, we suggest the application of 522 encapsulating 
NPs as NK cell stimulant for antibody-based cancer immunotherapy. 
 In chapter 2, we observed that 522NPs are similar or more effective in activating 
TLR7 and 8 reporter cells and inducing cytokines from human PBMCs. While 522NPs 
showed slightly enhanced upregulation of co-stimulatory molecules on BMDCs, antigen-
presentation via MHC I, was significantly enhanced by antigen+522NP treatment 
compared to antigen+Free522, which can be explained by enhanced antigen uptake 
mediated by antigen absorption on NPs. More importantly, 522NP immunization showed 
significantly enhanced prophylactic and therapeutic efficacy compared to Free522 
immunization. These findings imply that although 522 is a potent DC stimulant, in vivo 
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efficacy is limited in soluble form. Therefore, nanoparticulate delivery is a efficient drug 
delivery platform of TLR7/8 agonists. 
 In chapter 3, we achieved higher drug loading and acidic-pH responsive release 
kinetics by incorporating sodium bicarbonate within the PLGA NPs using double emulsion 
solvent evaporation method. In this study, new PLGA NP formulation showed enhanced 
in vivo T cell and NK cell response and augmented therapeutic efficacy in murine tumor 
model, compared to conventional PLGA NPs, which suggest that optimizing the NP 
formulation can enhance the efficacy of vaccine adjuvant. 
 In chapter 4, combination of nanovaccine and sunitinib reduced the MDSCs and 
Tregs population but did not show therapeutic advantage over nanovaccine as reduction of 
immune suppressive did not result in activation of CD8 T cells. Therefore, we further 
adapted anti-PD-L1 antibody to block the inhibitory PD-L1/PD-1 signaling. Combination 
of sunitinib and PD-L1 blockade not only reduced the immune suppressive cell population, 
but also increased the CD8 T cell activation at the tumor. Moreover, triple combination 
therapy triggered antigen-specific memory T cell response, which suggests the long-term 
efficacy against recurring tumors. Combined results indicate that modulating the tumor 
microenvironment can augment the therapeutic efficacy of nanovaccine by upregulating 
CD8 T cell responses at the tumor.  
 In chapter 5, when incubated with human PBMCs, 522GGNP significantly 
increased the NK cell activation markers. 522GGNP was also effective in potentiating in 
vivo NK cell cytotoxicity. Furthermore, 522GGNP co-treatment with cetuximab 
significantly increased the NK cell degranulation and induced IFN-ɣ secretion. These 
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results suggest that 522GGNPs are potent NK cell stimulant that can augment the ADCC 
of therapeutic antibodies.   
 
 Combined results suggest that nanoparticulate delivery of TLR7/8 agonist is a 
potent vaccine adjuvant for cancer vaccine therapy and antibody-based therapy. 
Additionally, recent studies show that combination of TLR agonists can promote 
synergetic effect with conventional oncology treatments including chemotherapeutics and 
radiation therapy, which suggest the versatility of TLR7/8 agonists as versatile immune 
adjuvants in a variety of cancer immunotherapy settings.  
 In our study, PLGA was utilized as polymer backbone as their biocompatibility and 
toxicity is well-established. Additionally, fabrication techniques to fine-tune the size and 
release kinetics was advantage of utilizing PLGA as drug carrier. However, other drug 
carriers including N-(2-hydroxypropyl)methacrylamide (HPMA), polyethyleneimine 
(PEI), chitosan, and liposomes are potent candidates for TLR7/8 agonist delivery platform.  
 For successful clinical translation of 522NP and 522GGNPs, further studies on 
safety is required. Although PLGA is a FDA-approved polymer, other formulation 
components including sodium bicarbonate, poly vinyl alcohol (PVA) and 522 need to be 
investigated. We expect negligible toxicity of sodium bicarbonate as concentration used in 
this study was comparable to that of buffered saline. A previous study reported that residual 
PVA on PLGA NPs affects their physical properties and cellular uptake, which suggest the 
need for investigating the effect of PVA on 522NPs and 522GGNPs in the future study. 
Currently, imidazoquinoline based TLR 7 agonists, imiquimod and resiquimod, are 
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approved only for topical treatments. Therefore, pharmacokinetics and potential adverse 
effects of 522 following SC and IM injection need to be investigated.  
 We also need to optimize the formulation of cancer vaccine and its immunization 
intervals. Here, we prepared the tumor cell lysates using repeated freeze-thaw cycle 
method, due to its simple preparation procedures and long-term stability of proteins. 
However, as TAA expression is highly heterogenic among the different tumor cell lines, 
examining the immunogenicity of tumor cell lysates prepared by different protocols is 
suggested.  
Optimization of immunization interval is also required. In this study, we 
immunized the animals daily for five consecutive days. However, previous studies report 
3~7 days as an optimal interval for T cell immunization and frequent antigen exposure may 
trigger T cell suppression. This will be particularly important for combination therapy with 
sunitinib as pre- or post- treatment of sunitinib appears to affect the antigen-presentation 
and T cell response of cancer vaccines. Therefore, mechanistic studies of immune cell 
responses following different doses and intervals of immunization is required to maximize 
the therapeutic efficacy and reduce the side effects of cancer vaccine.  
 With these issues addressed, we expect broad application of 522NP and 522GGNPs 
as vaccine adjuvant for cancer immunotherapy.  
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